{
    "GetResult": [{
        "description": "<p>Some description for the RA timeline.<\/p>",
        "events": [{
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Allison  McGeer<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 10\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local Study Follow Up Databases analysis on the reduction of disease caused by influenza virus with vaccination with GSK influenza vaccines <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-10 12:00:00",
            "high_threshold": 0,
            "icon": "turquoise2.png",
            "id": "7e632a7c-1d68-4b19-ab1f-3c1dfac035df",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "13-11869 (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local Study Follow Up Database analysis on the reduction of disease caused by influenza virus with vaccination with GSK influenza vaccines<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "turquoise2.png",
            "id": "22252e34-c0db-4e99-902d-761708e64505",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "13-11869 (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local Study Follow Up Modify influenza CE static and dynamic model to account for  pediatric efficacy and complication data <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "turquoise2.png",
            "id": "4ec3a268-7b9a-433b-9417-b778a8999dc3",
            "image": null,
            "importance": "0",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "13-11882 (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local Study Follow Up Modify influenza CE static and dynamic model to account for  pediatric efficacy and complication data <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "turquoise2.png",
            "id": "2c2fe3ce-ad79-4d11-804d-98e71e670f59",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "13-11882 (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Claudia Galindo<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Impact of Flu and Pneumonia vaccination among those >65 on hospitalization, pneumonia, COPD\u000d\u000aTotal budget: 150,000 €:\u000d\u000a2014: 50,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "60b6b1b0-ee0f-4f6e-93d7-4b69e6aea4fd",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "13-11885 (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Claudia Galindo<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Impact of Flu and Pneumonia vaccination among those >65 on hospitalization, pneumonia, COPD\u000d\u000aTotal budget: 150,000 €:\u000d\u000a2013: 100,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "314d8268-210a-4971-bcb6-28d76b97b0a7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "13-11885 (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "0197df86-b34c-438d-8a32-37f56002d719",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "AAFP 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "41eabf0a-f935-4444-958e-6a121ab38110",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "AAFP 2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "af4e662d-41d0-4a88-ae1c-70831f317c80",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "AAFP 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "94fa2dbb-1bb4-4aa4-a4d3-5af8132b0ca1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "AAP 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "24cc54e0-f0c0-485a-9d33-81b58c6c4b0f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "AAP 2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "7e6f5473-8335-4033-b6b1-dd8ef67dac75",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "AAP 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 22\/06\/2016 <br \/>until 23\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-23 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "85c984f6-a407-48a7-90d9-a07675fd1617",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-22 12:00:00",
            "title": "ACIP"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wendy A Keitel,Jonathan  Temte,Kristen R. Ehresmann,Mark H. Sawyer,S  Michael Marcy,Renée  R Jenkins,Nancy  Bennett,Carol J  Baker,Joseph A  Bocchini,H  Cody Meissner,Douglas  Campos-Outcalt,Larry K  Pickering,Sara  Rosenbaum,Tamera  Coyne-Beasley,Jeffrey  Duchin,Marietta  Vázquez<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/02\/2014 <br \/>until 27\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-02-27 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "99b54854-6952-44d6-a1db-c7aeb94eab2e",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2014-02-26 12:00:00",
            "title": "ACIP 2014  (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Renée  R Jenkins,Joseph A  Bocchini,Kristen R. Ehresmann,Nancy  Bennett,Jeffrey  Duchin,Carol J  Baker,Douglas  Campos-Outcalt,Mark H. Sawyer,H  Cody Meissner,Wendy A Keitel,Jonathan  Temte,S  Michael Marcy,Marietta  Vázquez,Sara  Rosenbaum,Larry K  Pickering,Tamera  Coyne-Beasley<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 25\/06\/2014 <br \/>until 26\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-26 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "80528bbb-1ce6-4843-a97d-c18df7260eda",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2014-06-25 12:00:00",
            "title": "ACIP 2014 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wendy A Keitel,Marietta  Vázquez,Jonathan  Temte,Larry K  Pickering,Sara  Rosenbaum,Tamera  Coyne-Beasley,Douglas  Campos-Outcalt,Nancy  Bennett,Carol J  Baker,Jeffrey  Duchin,Renée  R Jenkins,Kristen R. Ehresmann,S  Michael Marcy,Joseph A  Bocchini,Mark H. Sawyer,H  Cody Meissner<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 29\/10\/2014 <br \/>until 30\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-30 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "68f5aa16-48ed-4627-82ee-155fe7aca9d2",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-29 12:00:00",
            "title": "ACIP 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jonathan  Temte,Sara  Rosenbaum,Joseph A  Bocchini,Tamera  Coyne-Beasley,Marietta  Vázquez,Renée  R Jenkins,H  Cody Meissner,Nancy  Bennett,Jeffrey  Duchin,Wendy A Keitel,Kristen R. Ehresmann,S  Michael Marcy,Larry K  Pickering,Mark H. Sawyer,Carol J  Baker,Douglas  Campos-Outcalt<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 25\/02\/2015 <br \/>until 26\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-02-26 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "891a2117-e014-47e7-b190-f516b8cc5bc5",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2015-02-25 12:00:00",
            "title": "ACIP 2015 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Larry K  Pickering,Marietta  Vázquez,Tamera  Coyne-Beasley,Jonathan  Temte,Douglas  Campos-Outcalt,Kristen R. Ehresmann,Renée  R Jenkins,Wendy A Keitel,S  Michael Marcy,Sara  Rosenbaum,H  Cody Meissner,Jeffrey  Duchin,Joseph A  Bocchini,Mark H. Sawyer,Nancy  Bennett,Carol J  Baker<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 24\/06\/2015 <br \/>until 25\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-06-25 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c45ff2a7-cb18-4e0d-ad1f-eec5bdb4127a",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2015-06-24 12:00:00",
            "title": "ACIP 2015 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Mark H. Sawyer,Carol J  Baker,Nancy  Bennett,Renée  R Jenkins,Joseph A  Bocchini,Kristen R. Ehresmann,Tamera  Coyne-Beasley,Douglas  Campos-Outcalt,Marietta  Vázquez,Sara  Rosenbaum,Jeffrey  Duchin,Larry K  Pickering,Jonathan  Temte,S  Michael Marcy,Wendy A Keitel,H  Cody Meissner<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/10\/2015 <br \/>until 22\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-22 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "67c62f73-da3c-4b20-9463-e57cd8d76233",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-21 12:00:00",
            "title": "ACIP 2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>H  Cody Meissner,Carol J  Baker,Larry K  Pickering,Tamera  Coyne-Beasley,Renée  R Jenkins,Wendy A Keitel,Douglas  Campos-Outcalt,S  Michael Marcy,Kristen R. Ehresmann,Joseph A  Bocchini,Nancy  Bennett,Jeffrey  Duchin,Marietta  Vázquez,Sara  Rosenbaum,Jonathan  Temte<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 24\/02\/2016 <br \/>until 25\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-02-25 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "502ac575-67fb-4169-b9b1-b1b2850ff74d",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2016-02-24 12:00:00",
            "title": "ACIP 2016 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Douglas  Campos-Outcalt,Renée  R Jenkins,Larry K  Pickering,Marietta  Vázquez,S  Michael Marcy,Mark H. Sawyer,Jonathan  Temte,Sara  Rosenbaum,Tamera  Coyne-Beasley,Nancy  Bennett,H  Cody Meissner,Jeffrey  Duchin,Carol J  Baker,Wendy A Keitel,Kristen R. Ehresmann<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 22\/06\/2016 <br \/>until 23\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-06-23 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "4d148686-a618-4012-9403-0877289e9d43",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2016-06-22 12:00:00",
            "title": "ACIP 2016 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>S  Michael Marcy,H  Cody Meissner,Renée  R Jenkins,Mark H. Sawyer,Jeffrey  Duchin,Jonathan  Temte,Carol J  Baker,Marietta  Vázquez,Nancy  Bennett,Douglas  Campos-Outcalt,Wendy A Keitel,Joseph A  Bocchini,Kristen R. Ehresmann,Sara  Rosenbaum,Tamera  Coyne-Beasley,Larry K  Pickering<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 19\/10\/2016 <br \/>until 20\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-20 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "8cd6d606-9ded-4cfe-adfb-0d409ce9e570",
            "image": "http:\/\/www.cdc.gov\/vaccines\/acip\/images\/acip.png",
            "importance": "40",
            "link": null,
            "startdate": "2016-10-19 12:00:00",
            "title": "ACIP 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 29\/10\/2014 <br \/>until 30\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations. As planned in the EE plan.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-30 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "6088e981-e37b-42ed-9029-6b1c65597910",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-29 12:00:00",
            "title": "ACIP meeting "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/02\/2014 <br \/>until 27\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-27 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "28c7f5cd-097d-4dfd-b69e-62085783dc9d",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-02-26 12:00:00",
            "title": "ACIP meeting - Recommendations US"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "f2255e77-10cf-49b4-8489-488a1e8b5cbb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Adapt budget optimisation model"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "12df28e5-c7cc-4407-be9f-a671558feb43",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Adapt HE model to Brazil"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "193e8863-fee7-461c-9fac-9c6c806f0660",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Adapt HE model to China"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 31\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "c86a0a43-6db7-46dc-b1a8-5d06985613eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "Adapt HE model to Italy"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "2cc04568-f40b-47c0-8c4f-11e88aa91e33",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Adapt HE model to Mexico"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2012 <br \/>until 31\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "3a0be6c5-acf4-4721-a630-41dbac7f521b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-01 12:00:00",
            "title": "Adapt HE model to South Korea"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 31\/12\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "59800de9-8586-4b07-896c-602852702f59",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "Adapt HE model to Switzerland"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "bddd2d2f-e404-42a3-9695-3d86f75d4e6b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "AGS 2014 (May)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "284dc699-5230-4b41-a4c1-982cf415581f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "AGS 2015 (May)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b89cd5ff-a70d-4dc5-8f84-05e49acafab4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "AGS 2016 (May)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 30\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-30 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b5f6ffa4-5ae9-40e9-97b5-d9eca3b6dcd7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "American Academy of Family Physicians-AAFP (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c29b177a-d395-4012-8b4c-0579a9448691",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "American Academy of Pediatrics-AAP (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 31\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aas planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-31 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "96a5a703-38fc-4779-a4b6-40dce37d80e8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "American Geriatrics Society (AGS)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2012 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Q1 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "5f6fef50-d7dc-48d5-8149-e2331f010550",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2012-01-01 12:00:00",
            "title": "ap EPI Flu vaccine in HCW (200250)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "bda8babd-711b-4b2d-b2f0-636ad3b070a1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "APAC Wave 2 Recommending Bodies"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b1aa560d-a43d-438d-801d-7a5aeaae7ff7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "APAC Wave 2 Recommending Bodies 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5a5f8332-cc9e-4c2f-bec5-3c7c5baa8ef2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "APAC Wave 2 Recommending Bodies 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "6fa748c6-b841-4114-a780-3fe76efa03eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "APAC Wave 2 Recommending Bodies 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "175c25d8-7437-4c3a-8de2-b74944be56f5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "APAC Wave 3 Recommending Bodies"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c681d961-0430-4e0a-a928-2890098f99a5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "APAC Wave 3 Recommending Bodies 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "48a229e3-2c77-47a1-a4c7-d7f79e17ea7b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "APAC Wave 3 Recommending Bodies 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/07\/2013 <br \/>until 12\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>further dates to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-12 12:00:00",
            "high_threshold": 0,
            "icon": "imagenta2.png",
            "id": "2180a4b3-dac0-4981-884e-562e50abf389",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-12 12:00:00",
            "title": "APACI 2013"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "7dab4b9a-4067-4df7-8b61-7e69a4cdecc7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "APACI 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c58c9159-a176-4c13-a53c-b4474cac423e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "APACI 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "1ad3b9d9-35c1-405c-b2e8-fc442735a125",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "APACI 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>TBC\u000d\u000aExperts and update\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "051d2b81-51d0-4f28-bd13-67099ba30fc9",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "APACI Congress "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "33ad5a2a-6692-442f-b123-e7bf900083db",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "APACI meeting (TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Q2 2015<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "59d08621-9472-429e-b347-670456d8204d",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "apEPI-FLU-BOD AU SUPP"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2013 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Russia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Johannes  Hain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local study FU<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "7661ec0c-b8cb-455e-8944-8bff2bdf7057",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-11-01 12:00:00",
            "title": "apEPI-FLU-BOD RU CRT"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Q1 2016<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "4c0bc017-1e97-4f2f-af36-9dd48c334626",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "apEPI-FLU-VE AU SUPP"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>date to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "3cbd954d-5ac4-4bdd-ba47-358021ac7b2a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "APSIC"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 30\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Expers and update\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-30 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b545571e-2480-4b0b-8d22-d08c1702150a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "APSIC (Asia Pacific Society of Infection Control)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experst and updates\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "4deea262-b47e-4af1-a716-d5b572e3e369",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "APSIC Congress (Taiwan)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Lee  Ping In,Cissy  Kartasasmita,Chow  Chun Bong,Tawee  Chotpitayasunondh,Robert  Booy,Ian  Barr,Li Min  Huang,Yuen  Kwok Yung,David  Smith,Lance  Jennings,Shelley  De La Vega,David  Isaacs,Lau  Yu Lung,Peter  Richmond,Woo-Joo  Kim,Hee  Jin Cheong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/10\/2014 <br \/>until 26\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-26 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "59e5dafc-320f-4130-ab20-9df945e6eaed",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-26 12:00:00",
            "title": "Asia-Pac Regional Advisory Board (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Yuen  Kwok Yung,Robert  Booy,David  Isaacs,David  Smith,Woo-Joo  Kim,Shelley  De La Vega,Lau  Yu Lung,Ian  Barr,Lee  Ping In,Lance  Jennings,Li Min  Huang,Cissy  Kartasasmita,Hee  Jin Cheong,Tawee  Chotpitayasunondh,Peter  Richmond,Chow  Chun Bong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 15\/11\/2015 <br \/>until 15\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-15 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "2b190684-3ab7-4376-8803-4fb7b6a04196",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-15 12:00:00",
            "title": "Asia-Pac Regional Advisory Board (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Robert  Booy,Li Min  Huang,Yuen  Kwok Yung,Lau  Yu Lung,Woo-Joo  Kim,Cissy  Kartasasmita,Chow  Chun Bong,Hee  Jin Cheong,Lance  Jennings,Tawee  Chotpitayasunondh,Ian  Barr,Lee  Ping In,David  Smith,David  Isaacs,Shelley  De La Vega,Peter  Richmond<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/11\/2016 <br \/>until 13\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-13 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "c73c8b5c-0451-4068-9624-d3e8a2199b9f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-11-13 12:00:00",
            "title": "Asia-Pac Regional Advisory Board (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/02\/2014 <br \/>until 02\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-02 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "f3ff51ad-11a3-46a6-945f-7294350adc0a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-02 12:00:00",
            "title": "ATAGI  2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/02\/2016 <br \/>until 07\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-07 12:00:00",
            "high_threshold": 0,
            "icon": "red2.png",
            "id": "c0d9c0ec-ff33-472a-9c1d-de37d1d9e7b9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-07 12:00:00",
            "title": "ATAGI  2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 01\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "red.png",
            "id": "64384c4e-5fd5-4b9e-8fa8-ccb3ae0d4d1e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "ATAGI 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "11883c96-27c1-484c-9b5b-f398f5e5b2a8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "ATAGI meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d6ef493a-2d55-4ada-b9a2-a57d5f57a2aa",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "ATAGI meeting - Recommendations - Australia"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>European approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "b705d195-6e94-45b9-a363-6e4f610c5823",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-18y) (European approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2012 <br \/>until 01\/08\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>European filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "53b4eb50-98e6-473c-8b26-6190da914764",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-08-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-18y) (European filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>European launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c38e59a1-dad7-47cf-b8e6-7237474f7b4d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-18y) (European launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "344457b6-eec6-42ad-a884-179e81b61c5b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-49y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2012 <br \/>until 01\/08\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "eb1d8b8f-72a3-4b68-9b92-3acabcdf8918",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-08-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-49y) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "329d5b6f-581d-4c8f-a4b7-5807dea35931",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "AZ Medimmune Flumist QIV (2-49y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €50,000\u000d\u000aCSR: Q2 2015<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "c43cccfd-b0a7-4ede-87f9-bc487a352ebe",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "B strain mismatch among adults"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €50,000\u000d\u000aCSR: Q2 2016<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "2edc5205-fd97-4b29-9814-09541d2df635",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "B strain mismatch among children"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ced40949-ff39-4315-b9ce-1c5f0d58ca26",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "Baxter Preflucel TIV (18y+) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "92ed3114-5f53-4362-a8c5-4dcaf485e604",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-08-01 12:00:00",
            "title": "Baxter Preflucel TIV (18y+) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e9755a8a-a335-4402-982e-120c075c5a36",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Baxter Preflucel TIV (18y+) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "fee74869-47f2-4af0-92e1-5db299cab8d3",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "BKVJ (German Federal Pediatric Group)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "2865dec2-7b12-4f1f-beb1-b7fdb48ee13c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "BKVJ (German Federal Pediatric Group) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "8755577f-f02a-4775-b9a8-47b77b4bedd9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "BKVJ (German Federal Pediatric Group) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b24771bb-3553-4d66-b979-ff3ea6129079",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Brasil (SVS Recommending Bodies)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d726f4c1-ebcf-473a-901f-8e8bfd24b0d5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Brasil (SVS Recommending Bodies) - Recommendations Q1 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "344f877a-0366-4722-8b5e-75111771b931",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Brasil (SVS Recommending Bodies) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "32f075b1-c052-444b-b46d-253f0f644160",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Brasil (SVS Recommending Bodies) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "af249d54-1b29-4e7f-bd10-0d44d7fcaf6a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Brasil (SVS Recommending Bodies) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "2489d191-507a-4b13-b03f-2f7a771c81b5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Budget optimisation model"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "9bc2dce5-1590-4e9b-9088-da906ac55fc3",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Budget optimisation model #2"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Clinical and Financial burden of influenza in the US by type \u000d\u000aBetter understand the clinical consequences of influenza illness by type A and B \u000d\u000a1) Estimate the proportion of influenza cases seen at various healthcare setting by type                                             \u000d\u000a2) Estimate the healthcare resource utilization at the various settings by type  \u000d\u000a3) Estimate Direct medical costs by type \u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "a51906d7-73e1-4be1-8ffd-0e49dfd5bd04",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Burden & Cost Influenza A and B in US (HO-13-12299)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Retrospective BoD of FluA vs. B in pediatrics Study will yield  comprehensive information on the cost of hospitalization due to influenza for children, by combining IMPACT surveillance data with detailed hospital resource utilization data. \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "8c5fc196-8892-4eaa-a82a-9cd6480eaa48",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "Canada #25207 Influenza A & B in pediatric populations, Burden of Disease in Canada Retrospective BoD of FluA vs. B in pediatrics"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Outpatient & hospitalization influenza rates (lab. confirmed or derived by a case definition) and Direct Medical Costs. Study will yield  comprehensive information on the cost of hospitalization due to influenza for adults, by combining SOS surveillance data with detailed hospital resource utilization data. Better understand the magnitude of  influenza associated outpatients visits that are then hospitalized. Cost of strain specific BoD from SOS Vaccine effectivenes BoD study\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "c48029cc-8a39-4e10-ac26-3422f3c691f2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Canada #844562 Cost of Severe Influenza  Cost of strain specific BoD from SOS Vaccine effectivenes BoD study"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Leyla Hernandez<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 5,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown2.png",
            "id": "c178fbff-6b51-4777-8b68-5f6f8e22468a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "China literature review"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/01\/2014 <br \/>until 26\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Beijing<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Epi and BoD 1<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-26 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "63965835-8ad8-442d-b203-b9dc23d72774",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-26 12:00:00",
            "title": "China LOC Advisory Board "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "77305d2a-f024-4a7f-90fb-9527793ca582",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Competition slide kit update"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1b315afc-f0f9-4a43-b26e-9f24e613e4ce",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Consensus Conference"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "1ea12443-b4c0-49ed-991c-52917b0f8be4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Consensus Conference 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "2b8ac8d0-76f3-406d-af36-98e4abd4903b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Consensus Conference 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "7351196b-9dfd-4ed0-a2b9-fd06357bd126",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Consensus Conference 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b90c253d-3e07-4d04-b37d-fd138bc3541b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "Core scientific evidence update (e.g. D-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "7ad6219f-6ced-4aa6-8896-1df076b5df89",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Core scientific evidence update (e.g. Q-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Details TBD<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "brown2.png",
            "id": "b336d3a4-d634-4a12-92ed-37e975b2b1b0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "Cost effectiveness model for Germany"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Evidence that supports routine vaccs with GSK flu vacs in reduction of disease caused by flu virus with economic consequences of non vac. Should show vac reduces burden and highlight value of case and complication avoidance -Collect and comparison of costs and cases in vaccinated and non vaccinated groups \u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "brown2.png",
            "id": "5e006a62-4178-417a-bcca-4363ef7b6765",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Database analysis on the use of GSK assets in the reduction of disease caused by influenza virus"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "63471166-7f5d-420b-93ff-e6eaf449b161",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "DEGAM (German GPs Meeting)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "2f22f1a6-6d40-41d3-81fa-f7a505f16005",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "DEGAM 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "f8083185-a2af-4135-8602-96fb8f65f079",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "DEGAM 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "0b43374e-89b5-4241-a3f7-b3c4690f80f1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "DEGAM 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan\u000d\u000a\u000d\u000aDate to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "ba279f10-9685-4ea6-a14c-7863f87e1676",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "DG Sanco Childhood Immunisation Conference"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 30\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update As planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "e92dc716-6c64-45cc-abd3-cfdbaca1a2f4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "DGAUM (German Geriatric Society)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c95c71c7-7acb-48c7-9884-f22eebadcf33",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "DGAUM 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b18f31c3-eafb-4034-9b44-a5619eb1dde6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "DGAUM 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "6b89082c-98c4-41cf-98aa-8f466b5188bb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "DGAUM 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "1ba8fb02-e190-44be-aaab-56551beb35c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "DGIM 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b9945d37-0b8d-4af3-b6a1-df83c8005c11",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "DGIM 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "712ab297-00da-49af-a869-f7ea5d11fc2f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "DGIM 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5d5d3b0a-d5c0-4772-b956-f3bbad820b3f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "DGIM Congress (Germany)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "48587187-9ea5-47e1-baeb-bf7eae7935d0",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "DGIM Congress (Germany) - Share new data"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "115ace89-f8f8-4496-a44a-6fd77551c633",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "DGPI (German Peds Meeting)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "6f64381b-3a9f-4844-a358-0022324eeb9b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "DGPI (German Peds Meeting) - Experts and update - Germany"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "844f79e1-9180-4183-b5db-c95bf2e99a52",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "DGPI 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5906117d-f1bd-4f2a-852b-efbb9eec94c3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "DGPI 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b4ce5ec2-1805-47c6-a975-8bcc43d38a88",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "DGPI 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Algeria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Algeria approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4f509326-cbe5-4e00-8446-24106c5117eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "D-QIV 3y+ (Algeria approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Algeria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Algeria filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "431ddc8c-5392-4667-9c38-2fe2ad370d3a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Algeria filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Algeria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Algeria launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "1f9b09c6-83d6-4491-956e-68e795e5d8a8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Algeria launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "15209c25-6000-4bc5-9c2c-a43df650ef61",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "D-QIV 3y+ (Australia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2012 <br \/>until 01\/03\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "95a74a61-3c0e-48fc-af27-16955b139741",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-03-01 12:00:00",
            "title": "D-QIV 3y+ (Australia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0de4cc73-6829-49c3-b647-0c5bf61cbc49",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Australia launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Austria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Austria approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "507a6589-e5e4-499d-9b48-bd5d08e8a9c9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "D-QIV 3y+ (Austria approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Austria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Austria filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "00fd807c-5c90-49cb-8667-cb169e577342",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Austria filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Austria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Austria launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e724845e-972d-49e8-9fba-5a01fe35043a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 3y+ (Austria launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Belgium approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4ac4a2a4-f879-44ca-9748-58f4dbfed958",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "D-QIV 3y+ (Belgium approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Belgium filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "dfcc8583-d8e3-49a6-8f3d-1950fed9592f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Belgium filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Belgium launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ca035543-da40-46cc-9ec3-3f84d63c05aa",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Belgium launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Brazil approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0f6b0719-3b2d-4474-b9f3-ce28b2258958",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 3y+ (Brazil approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Brazil filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4cced509-bccb-4d90-92ae-ab440fbed3b4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (Brazil filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Brazil Launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f5df646c-d086-4a5a-bba6-facb890762b9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Brazil launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Bulgaria<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Bulgaria filing (TBC)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c18da0ca-e728-4a93-9ec1-74c5fafad434",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Bulgaria filing, TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2020 <br \/>until 01\/01\/2020 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>China aproval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2020-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "1add9b11-04b7-4678-804a-7274ae82bf34",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2020-01-01 12:00:00",
            "title": "D-QIV 3y+ (China approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>China filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e128afe3-5b76-4b2a-b125-f263e30ecc3b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (China filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2021 <br \/>until 01\/01\/2021 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>China launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2021-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a7d10d3d-f346-423e-a7be-4a91db21fa12",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2021-01-01 12:00:00",
            "title": "D-QIV 3y+ (China launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Cyprus<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Cyprus filing TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "70aa640b-bdc7-419f-9804-dd03fe2090aa",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Cyprus filing, TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Czech Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Czech Republic approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5c044730-f8da-4a1c-8be6-610a9d724c95",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "D-QIV 3y+ (Czech approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Czech Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Czech Republic filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "7482dcc5-d9a9-4408-9e68-286a07472c00",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Czech filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Egypt<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Egypt filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6d566da3-b4bb-4d9f-b642-23a4f25ef0de",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Egypt filing) "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2013 <br \/>until 01\/05\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>France approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4aa95dd9-092a-4eeb-868b-335d687592ba",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-05-01 12:00:00",
            "title": "D-QIV 3y+ (France approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2012 <br \/>until 01\/03\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>France filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4df717e3-2626-4e98-badf-93a4ecb86c57",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-03-01 12:00:00",
            "title": "D-QIV 3y+ (France filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>France launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "8db5f2a9-b9a9-41a2-b7cc-2fc4af48851a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "D-QIV 3y+ (France launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Germany approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "00c1759c-cf73-49ec-af14-f9dafa6f887c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (Germany approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2012 <br \/>until 01\/03\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Germany filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "309bebed-dfdb-497d-bd75-12d2b70aa444",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-03-01 12:00:00",
            "title": "D-QIV 3y+ (Germany filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Germany launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3974e0a3-5a58-44b9-8822-d712e81f78c8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "D-QIV 3y+ (Germany launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Greece<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Greece approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3ada9da3-1c05-41d6-9b29-838c65efc96f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "D-QIV 3y+ (Greece approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Greece<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Greece filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "748568b3-ea19-422e-9ef9-c77cca47ceef",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Greece filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Greece<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Greece launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ae1b1be8-8722-4501-979f-bb7985613a3f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "D-QIV 3y+ (Greece launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Hong Kong<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Hong Kong approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4528a27d-2139-48ba-8483-4f954400e907",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "D-QIV 3y+ (Hong Kong approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2013 <br \/>until 01\/05\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Hong Kong<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Hong Kong filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "dea06187-23df-4888-bb73-43055a29452b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-05-01 12:00:00",
            "title": "D-QIV 3y+ (Hong Kong filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Hong Kong<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Hong Kong launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5d19d5d0-9c7a-4caa-af34-f3fe99903fee",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 3y+ (Hong Kong launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Indonesia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Indonesia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5513e330-ae5d-4624-a92b-a9f3310c0f58",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Indonesia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Indonesia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Indonesia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0e46a608-c39d-4367-87e3-1d18f7e908c1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "D-QIV 3y+ (Indonesia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Indonesia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Indonesia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a355f291-8ef0-4298-874a-6cba08a86677",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Indonesia launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Israel<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Israel approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "9e471d3b-a6f9-4435-8335-2871b1ac58b3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "D-QIV 3y+ (Israel approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Israel<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Israel filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "841ebf5a-9d42-44e5-93ff-dd7789fa1406",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (Israel filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Israel<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Israel launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6f834737-20d1-4bc2-b853-763a1a7043c1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Israel launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Italy approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "18b647b1-42a0-4a4f-b023-24bf763ce4a5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Italy approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Italy filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "cd4f8b2c-f191-48cb-b0b2-4a8f82f4a6e8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Italy filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 01\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Italy launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "07b6b263-c400-4a70-a84f-751b0f258cde",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "D-QIV 3y+ (Italy launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Latvia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Latvia filing TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c88abbfe-abd1-4b21-9c47-50b3a86190db",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Latvia filing, TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Macao<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Macau approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a1fc3cfb-27e2-4bfb-8bb4-37b50e088fa6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "D-QIV 3y+ (Macau approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2013 <br \/>until 01\/05\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Macau filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c8c47960-3194-4af6-bfb5-ba42bf8be958",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-05-01 12:00:00",
            "title": "D-QIV 3y+ (Macau filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2013 <br \/>until 01\/12\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Macao<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Macau launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "84538f16-0439-4c89-8d73-1c6617345914",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-12-01 12:00:00",
            "title": "D-QIV 3y+ (Macau launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Malaysia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Malaysia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "2dd70883-314e-4c71-81fb-d56058829106",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Malaysia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Malaysia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Malaysia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6021520e-f6a3-44b9-972d-943b202f11b7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "D-QIV 3y+ (Malaysia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Malaysia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Malaysia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f9a2dc3f-99f5-4d0d-b195-c6db5739bb43",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Malaysia launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Netherlands<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Netherlands approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e8957dfb-1f8c-4d10-bbfc-e767d6e0a594",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Netherlands approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Netherlands<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Netherlands filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "102a9dee-4a48-4665-8aae-8b4c97ae7ff2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Netherlands filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Netherlands<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Netherlands launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "429f04cc-7d9c-4080-a694-300e7de3abc3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "D-QIV 3y+ (Netherlands launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New Zealand approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "b28a96f4-b52f-40d5-97b4-b4c7a9b3f2e1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "D-QIV 3y+ (New Zealand approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New Zealand filing with updated file approved in Australia<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3010c0c3-e09d-4164-908b-6132c777879c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (New Zealand filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Philippines<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Philippines filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3241a993-72ad-4e76-80ba-42bf13bef324",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "D-QIV 3y+ (Philippines filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Philippines<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Philippines launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "85ca83e2-5e4e-4e3c-a7de-aad2de3b60ac",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Philippines launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Poland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Poland filing TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6ca3393b-5735-408e-b73d-2e03f65126a8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Poland filing, TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Portugal<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Portugal approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "2779a16a-ed79-4b41-9ea2-c5cbff3cb82a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Portugal approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Portugal<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Portugal filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c82d7708-6fd8-4bab-9e9c-f0889f6c1d8a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Portugal filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Portugal<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Portugal launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6bbc3c02-a8f9-4994-8a8a-a1bc317e4dc5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "D-QIV 3y+ (Portugal launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New Zealand approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5d391823-35a2-4995-bb52-9fc87a8dfe46",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "D-QIV 3y+ (Q-QIV ?) (New Zealand approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2013 <br \/>until 01\/11\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New Zealand filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5944987a-3b91-46d7-b6dc-134b87e85279",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-11-01 12:00:00",
            "title": "D-QIV 3y+ (Q-QIV ?) (New Zealand filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New Zealand launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "dd9097db-b6eb-4ba2-8529-5f23518d3af2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Q-QIV ?) (New Zealand launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Romania<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Romania filing TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "89aa017f-298d-49ee-8e08-f000af5d3c65",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Romania filing, TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Russia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Russia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "606febb4-d4bd-4bb0-8c21-bfdd256b5946",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Russia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Russia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Russia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "55d8118c-1b6a-4bed-a0b1-498461baaaa1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Russia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Russia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Russia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "06380fdb-de89-4cff-bb9e-7b559d9e6404",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "D-QIV 3y+ (Russia launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 01\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Saudi Arabia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Saudi Arabia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "d615cb56-3f72-473c-9376-5abc3ee71e7c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "D-QIV 3y+ (Saudi Arabia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Saudi Arabia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Saudi Arabia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "bf32c1b8-d9da-4cd4-9ed0-a3e0129f5296",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Saudi Arabia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Saudi Arabia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Saudi Arabia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "54c738b2-ae6f-47d2-9b21-bedffeae9233",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "D-QIV 3y+ (Saudi Arabia lauch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Singapore<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Singapore approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a5aa56e0-0bcf-45dd-bf0e-b4ee2ba3b700",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Singapore NH\/SH approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Singapore<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Singapore filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4c36a83c-3bf7-45d1-b7cb-6d34285223c0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "D-QIV 3y+ (Singapore NH\/SH filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Singapore<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Singapore launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f157bf18-19d1-4365-a1ae-b5edc181b887",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Singapore NH\/SH launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Slovakia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Slovakia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f582cbd9-00a0-4f69-a81f-b590e1e6d580",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "D-QIV 3y+ (Slovakia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Slovakia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Slovakia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "778ade57-48cb-4cab-90cc-a9551111f576",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Slovakia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>South Korea approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e7bab73b-eab1-4b02-bd5d-212464e17471",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "D-QIV 3y+ (South Korea approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>South Korea filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3de277a4-0946-4faa-94ec-7b2100a90d2e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "D-QIV 3y+ (South Korea filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>South Korea launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "aaa7c8b5-c39d-44f8-97eb-f9b9b5eaf1f8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 3y+ (South Korea launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Spain approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5fefcb17-793e-4a99-9e81-e3c4f510c067",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 3y+ (Spain approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Spain filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0a9fdacb-e756-46d2-98c0-190818177499",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Spain filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Spain launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "992af75e-cd03-40df-88d8-62ed2cdd7474",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Spain launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2013 <br \/>until 01\/12\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Switzerland approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3e6093ad-6912-4b09-989b-eaad658a7e54",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-12-01 12:00:00",
            "title": "D-QIV 3y+ (Switzerland approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2012 <br \/>until 01\/03\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "8966e6be-bc0b-4a44-bcf4-b5befa69d172",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-03-01 12:00:00",
            "title": "D-QIV 3y+ (Switzerland filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Switzerland launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "134da611-4926-4a06-9d14-7c59eb4c151f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Switzerland launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/10\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Taiwan approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c00f03a1-fbfd-4a6f-9e83-c9ddff42b0a4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "D-QIV 3y+ (Taiwan approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2012 <br \/>until 01\/10\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Taiwan filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e6afee07-5d9e-4a69-bde2-4fafeafc63ac",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-01 12:00:00",
            "title": "D-QIV 3y+ (Taiwan filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2012 <br \/>until 01\/10\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Taiwan filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "488c77be-a696-4daa-9538-7befa660ceac",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-01 12:00:00",
            "title": "D-QIV 3y+ (Taiwan filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Taiwan launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0d70f28f-d8e3-438e-8683-478d53a3b3af",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 3y+ (Taiwan launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2015 <br \/>until 01\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Thailand approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "cf4abbdb-14ad-467d-87d0-8c34608c8f93",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-01 12:00:00",
            "title": "D-QIV 3y+ (Thailand approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Thailand filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "fe2f7feb-b55b-4873-b1f7-ce535b5be29f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (Thailand filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Thailand launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "dc0bf5aa-2948-49cf-845f-2ff39afe3962",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "D-QIV 3y+ (Thailand launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Turkey<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Turkey approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "7dd7edf0-e34c-4ffc-81f3-c6daa641b6e2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "D-QIV 3y+ (Turkey approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Turkey<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Turkey filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "02dcc639-6c5c-4efb-b45a-c30ec8e75433",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (Turkey filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Turkey<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Turkey launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "7ffba85d-e017-43b6-ae1c-6e49d805542e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "D-QIV 3y+ (Turkey launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>UK approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e78b780d-c71e-4c4c-8fc5-db86839561c1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "D-QIV 3y+ (UK approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2012 <br \/>until 01\/03\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>UK filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "1813b703-4d62-49ab-a265-2ec1195810b8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-03-01 12:00:00",
            "title": "D-QIV 3y+ (UK filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>UK launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "2a6da12c-2541-454e-878e-c4d6764bae2e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "D-QIV 3y+ (UK launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2012 <br \/>until 01\/12\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "68a23795-cfed-4aae-8f17-5291f757ed59",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-12-01 12:00:00",
            "title": "D-QIV 3y+ (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2012 <br \/>until 01\/12\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3244eed8-e66f-4c69-b516-b4cc1e813d54",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-12-01 12:00:00",
            "title": "D-QIV 3y+ (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/09\/2013 <br \/>until 13\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-13 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4f19d7a6-2f19-4214-adf6-483fd195d331",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-13 12:00:00",
            "title": "D-QIV 3y+ (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Canada approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "390556b8-6453-4cf7-ade9-ceb71de184dc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "D-QIV 6M+ (Canada approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Canada filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c7ea9efa-1b63-4bae-86a0-8d880a2652ed",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "D-QIV 6M+ (Canada filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Canada launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "fd9eab2f-b471-473d-b4f4-459e995a93f1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "D-QIV 6M+ (Canada launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "959637a2-439e-4844-9e58-3929848b4997",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "D-QIV 6M+ (EU approval; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e7e340ff-2266-4664-af00-8b4d6150cf40",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "D-QIV 6M+ (EU filing; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6f5d9432-ddba-4565-85f8-e966ab739e68",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "D-QIV 6M+ (EU launch; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2018 <br \/>until 01\/03\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Japan approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "9fdf2857-f428-4ee5-ad08-bad35f81ccee",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-03-01 12:00:00",
            "title": "D-QIV 6M+ (Japan approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Japan filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "69756bad-1a02-4ff8-b595-397ee37ca7a4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "D-QIV 6M+ (Japan filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2018 <br \/>until 01\/09\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Japan launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a0e630ec-1193-443c-a3e7-89c0834e1684",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-09-01 12:00:00",
            "title": "D-QIV 6M+ (Japan launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2016 <br \/>until 01\/08\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "4977a066-923e-4c5f-b32a-191cbff2f72f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-08-01 12:00:00",
            "title": "D-QIV 6M+ (US approval; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "58468078-ffbb-4637-93e7-26ab14c4083c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "D-QIV 6M+ (US filing; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "b664a85e-28e5-451f-b965-f48036e222ec",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "D-QIV 6M+ (US launch; variation)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Etienne Sokal,Karl Logghe,Andre Vertruyen,Steffan Van Eldere,Martine Docx,Marc Verghote<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2011 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>EU, tropical and sub-tropical countries<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>6-35 months indication<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e4b12e98-4475-4857-9737-8dcfa98c0f90",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2011-10-01 12:00:00",
            "title": "D-QIV-004 (6-35 months indication)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 30\/04\/2014 <br \/>until 30\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Fitting a dynamic influenza model  to UK surveillance data Methodology manuscript. Proposed authors: E. Thommes, C. Bauch, G. Meier,  (TBD) A. Chitkara. Suggested Target Journal - Vaccine.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-30 12:00:00",
            "high_threshold": 0,
            "icon": "brown2.png",
            "id": "60d609de-47e0-4d91-be5e-6f2d31bb581a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-30 12:00:00",
            "title": "Dynamic cost effectiveness model UK (1 of 2)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/12\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A health economic analysis of switching from  TIV to QIV in the UK. Proposed Authors: E. Thommes, C. Bauch, G. Meier,  (TBD)A. Chitkara, others? Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "brown2.png",
            "id": "d6339a3e-a24c-4512-aafc-c0a80b800a40",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-31 12:00:00",
            "title": "Dynamic cost effectiveness model UK (2 of 2)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan\u000d\u000a\u000d\u000aDate to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "be6d037e-97c0-454a-ac00-9eea22006b79",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EAPS (Europe TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Barcelona<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Date to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "803ca03f-d7c3-4044-90c6-5edd7a4fd856",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "EAPS 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "b3ab2e4b-3d51-44be-9f1a-faf6b280ea35",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "EAPS 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "36f3c2ea-b439-41ab-9c37-bff368cfc27d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "EAPS 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 17\/10\/2014 <br \/>until 21\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update. As planned in the EE plan.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-21 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "61c2e9ea-8365-4dff-9510-96d97972e508",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-17 12:00:00",
            "title": "EAPS Congress (Spain)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "69ceb4e2-ea4e-4b78-842d-455fc7c6d544",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "ECCMID (TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/05\/2014 <br \/>until 13\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Barcelona<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-05-13 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "adc5920d-921e-487f-b4fc-3623c86ea5c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-10 12:00:00",
            "title": "ECCMID 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "69e6c9c6-422d-4d53-8e9e-3b0d3ece4bcd",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "ECCMID 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "3a223500-ec57-4ad0-8e8b-517fe13c58a9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "ECCMID 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 25\/05\/2015 <br \/>until 28\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates \u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-28 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "06d7c520-6790-4931-85d2-165c920d1869",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-05-25 12:00:00",
            "title": "ECCMID Congress (Denmark)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/05\/2014 <br \/>until 13\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-13 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "fa1ee6b4-2c62-4b66-82e7-3e7df4eaf304",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-05-10 12:00:00",
            "title": "ECCMID Congress (TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/04\/2014 <br \/>until 13\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Epi and BOD 1<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-13 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "4aeef10c-62c6-42ec-9e13-6b2b5fda0e48",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-13 12:00:00",
            "title": "Emerging Markets Regional Advisory Board (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 17\/05\/2015 <br \/>until 17\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Epi and BOD 2<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-17 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "024fbf16-c715-4039-acb5-3cf6f6ccb2dc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-17 12:00:00",
            "title": "Emerging Markets Regional Advisory Board (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>BOD in Manitoba population based database analysis, Burden of Influenza - GP Visits, hopitalization and mortality\u000d\u000aFurther details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "0313d2b6-af13-4f4e-8e95-edb1928fd510",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Epi Canada"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/11\/2014 <br \/>until 02\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Nov 2014. Surveillance system \/ Clinical characteristics and strain circulation of Influenza B in Brazil<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-02 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "96a29017-a1a6-4b04-ba32-4792bfe069e2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-02 12:00:00",
            "title": "EPI-FLU_BOD Brazil Epi of Flu B in Brazil (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/03\/2014 <br \/>until 02\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit March 2014. Surveillance system \/ Clinical characteristics and strain circulation of Influenza B in Brazil<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-02 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "516c140a-5381-4cba-beb1-81c9d32fa35c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-02 12:00:00",
            "title": "EPI-FLU_BOD Brazil Epi of Flu B in Brazil (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/03\/2014 <br \/>until 02\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit March 2014. Surveillance system \/ Clinical characteristics and strain circulation of Influenza B in Brazil<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-02 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "69a97441-8c80-4191-bfd6-b25ff4819d29",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-02 12:00:00",
            "title": "EPI-FLU_BOD Brazil Epi of Flu B in Brazil (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/06\/2013 <br \/>until 02\/06\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start June 2013. Surveillance system \/ Clinical characteristics and strain circulation of Influenza B in Brazil<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-06-02 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "f5ff1f23-9a63-44ed-8e30-4691e63e1aae",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-06-02 12:00:00",
            "title": "EPI-FLU_BOD Brazil Epi of Flu B in Brazil (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/10\/2015 <br \/>until 04\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q4 2015. European Influenza surveillance system: Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-04 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "73bd8d02-ca6c-4682-bb4d-080ca05b9e20",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-04 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2010 <br \/>until 01\/12\/2010 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Dec 2010. European Influenza surveillance system: Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2010-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "393d0af8-3281-4255-a949-a951e2dbc23f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2010-12-01 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Allison  McGeer,Alan Hampson<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/02\/2010 <br \/>until 07\/02\/2010 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Feb 2010. European Influenza surveillance system: Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2010-02-07 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "727667f5-2fc3-4385-903a-c7648087c760",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2010-02-07 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/10\/2015 <br \/>until 04\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q4 2015. European Influenza surveillance system Extension : Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-04 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "b5695ffa-a9ca-468b-a848-21111a1cac7a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-04 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) extension (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/12\/2010 <br \/>until 05\/12\/2010 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Dec 2010. European Influenza surveillance system Extension : Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2010-12-05 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "f2966399-9f36-4684-9063-f69ff8484144",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2010-12-05 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) extension (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/01\/2010 <br \/>until 03\/01\/2010 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start 2010. European Influenza surveillance system Extension : Multi-country assessment of burden of influenza in General practice<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2010-01-03 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "a5af84df-85d2-40c5-9695-70f93b1bce00",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2010-01-03 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT (IBGP) extension (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Burden of influenza B in Eu. Severity, age class distribution and health care consumption economic data for France. \u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "7c05e8a0-353e-4488-a1f3-006501434024",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "EPI-FLU-014 BOD EUR CRT IBGP2 (Influenza B in general practice)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2011 <br \/>until 01\/12\/2011 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>VE Canada (Vaccine effectiveness)\u000d\u000aBudget: Millions €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2011-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "27d10605-7bfb-4b68-aa9b-60134d2484d5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2011-12-01 12:00:00",
            "title": "EPI-FLU-019"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2016 <br \/>until 01\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>VE Canada (Vaccine effectiveness)\u000d\u000aBudget: Millions €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "96698d72-9ff1-44db-8a55-a0d4a57d9e1c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-12-01 12:00:00",
            "title": "EPI-FLU-019 (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Claudia Galindo<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>VE Canada (Vaccine effectiveness)\u000d\u000aBudget: Millions €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "0be1456c-cd99-4cbb-9d1a-93437794f836",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "EPI-FLU-019 (end)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Effectiveness of seasonal influenza vaccine in the prevention of hospitalization in adults 2011-2012, 2012-2013\u000d\u000aCanadian Effectiveness and BOD Study\u000d\u000aVaccine effectiveness and sentinel surveillance for influenza requiring hosptial admission in elderly Canadian adults 65 years of age and older\u000d\u000aMulti-year study (2011-2012, 2012-2013, 2013-2014)\u000d\u000aAuthors and Target Journal TBC.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "5d203cb2-1937-46d0-a1f2-585625f05791",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "EPI-FLU-019 VE CA  (116317)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/12\/2016 <br \/>until 27\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-27 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "ae542818-371e-4e3f-83c4-fab40da7d673",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-12-04 12:00:00",
            "title": "EPI-FLU-019; VE Canada (Vaccine effectiveness) (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/09\/2015 <br \/>until 06\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study end Sept 2015<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-06 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "a7fe44ec-5191-4407-9b50-ba4c3a332c00",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-06 12:00:00",
            "title": "EPI-FLU-019; VE Canada (Vaccine effectiveness) (end)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/12\/2011 <br \/>until 04\/12\/2011 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Dec 2011<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2011-12-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "1138f63d-6d0e-42a5-a136-04ae722490e3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2011-12-04 12:00:00",
            "title": "EPI-FLU-019; VE Canada (Vaccine effectiveness) (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2013 <br \/>until 01\/12\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aFSFV May 2013\u000d\u000aLSLV Dec 2013\u000d\u000aCSR Mar 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "6e0cdac6-559a-4261-841a-1c92ffbecab3",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-05-01 12:00:00",
            "title": "EPI-FLU-020 VS AU CRT (116328)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Prospective surveillance study comparing the clinical course of primo- and reinfection with laboratory-confirmed influenza in pre-school children (NOT FINAL TITLE)\u000d\u000aAuthors and Target Journal TBC\u000d\u000aMOCK DATES ONLY - ACTUAL DATES TO BE ADDED<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "eb9726ef-da84-438d-8013-37e3d43613d8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "EPI-FLU-021 BOD DE SUPP  ISS (116408)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Dec 2013<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "c5d243db-2fb4-4470-8d38-f33c66a37c5a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "EPI-FLU-021 BOD DE SUPP (116328) Prospective study comparing clinical course of primo and reinfection with influenza in children 2-5 years"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A Case-Control Study to Measure Seasonal Influenza Vaccine Effectiveness Against laboratory Confirmed Influenza Hospitalizations in a Reference Hospital of Central Italy (NOT FINAL TITLE)\u000d\u000aAuthors and Target Journal TBC\u000d\u000aMOCK DATES ADDED - ACTUAL DATES TO BE ADDED<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "450f171d-8730-4699-83da-c24ef39efe49",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "EPI-FLU-023 VE EU SUPP ISS (116599)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US INFLUENZA HOSPITALIZATION BY AGE CLASS. Author and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "b4c108ab-388e-4bc6-a9a9-40744e9994e1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "EPI-FLU-024 BOD US (DB) (116730)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Attack rate of influenza in unvaccinated populations\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "87e7f5a8-b0aa-45d6-b7aa-621bcad59c14",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "EPI-FLU-025 BOD CA    Natural Attack Rate Study  117102 (HO-12-12530)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US outpatient visits by age class. Authors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "66ce1a92-cc92-4c3b-890c-d60d083f56db",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "EPI-FLU-026 BOD US DB (DB)  (117233)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/09\/2013 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Planned publication - Mortality & hospitalization by risk status. Authors and Target Journal TBD<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "c257b93f-a8ba-484e-9f44-7189a66b2fe0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-04 12:00:00",
            "title": "Epi-flu-BoD 018 (116273)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Impact of mismatch\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "a9fc1fe2-7c78-423c-9733-39bfa54e7838",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "Epi-flu-BoD 018 (116273) EPI-FLU-024 BOD US (DB) (116730) EPI-FLU-026 BOD US DB (DB) (117233)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2013 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Nov 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "808d8cd2-4ec8-48aa-b30d-d39023b83923",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-06-01 12:00:00",
            "title": "EPI-FLU-BOD Brazil Epi of flu B in Brazil"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2013 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>India<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Johannes  Hain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Local study FU\u000d\u000aCSR: Q2 2015<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "c4b55bde-6de3-47eb-b51e-cbebd5b03e83",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-12-01 12:00:00",
            "title": "EPI-FLU-XXX Quadriv India CRT"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c9f8f7d1-7c75-413e-be13-a67f40baa7d1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "ESPID 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "f43dd6f4-4eef-456b-92a3-0a97377ff562",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "ESPID 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "Dark_blue2.png",
            "id": "7eecd4a3-4c49-4c50-9098-c9b0cafee137",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "ESPID Congress (TBC) Medical Booth"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 30\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Congress presentations\u000d\u000aShare new data\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "1aa24770-e1cf-4f9c-a328-541f38727d13",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "ESPID Congress (TBC) Symposium\/stand-alone meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "64d00d73-daaa-4c7a-ba02-b230c1ead602",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "ESPID Congress (TBC) Symposium\/stand-alone meeting (D-QIV>6month)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/01\/2014 <br \/>until 06\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Congress presentation to share new data - date to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-06 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "868f8467-863b-46a1-8c19-76cea727c04b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-06 12:00:00",
            "title": "ESPID congress 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 14\/09\/2014 <br \/>until 17\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-17 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "0788ac0f-d90b-4bb7-a8b1-71e8ee17a1f7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-14 12:00:00",
            "title": "ESWI (EU) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "3b30b528-1df2-4c24-b8b2-d8c8f3fdaa91",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "ESWI (EU) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "244da620-89f5-49b5-a840-a8d0302516c0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "ESWI (EU) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 14\/09\/2014 <br \/>until 17\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-17 12:00:00",
            "high_threshold": 0,
            "icon": "Dark_blue2.png",
            "id": "c90842e6-fa63-490b-9759-79bce60d93bf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-14 12:00:00",
            "title": "ESWI Congress (Latvia)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Dark_blue2.png",
            "id": "a481726f-5644-4bab-950f-1fe8879d294e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "EU DGSANCO  Childhood Immunisation Conference"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan\u000d\u000a\u000d\u000aDate to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "Dark_blue2.png",
            "id": "13c0e2eb-9632-4078-aacc-9382762e36dc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EU DGSANCO Childhood Immunisation Conference"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body meeting<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "6a85d702-0fc1-4d3e-9aa9-db729eb610a2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "EU Wave 2 Recommending Bodies"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "0029d9c9-9a50-4c42-8bbf-ff20cd427d40",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "EU Wave 2 Recommending Bodies - Recommendations - Europe"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body meeting<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "49592231-3dce-459d-9df1-533c76b45d3b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "EU Wave 2 Recommending Bodies (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body meeting<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "965f483d-f8c8-43fd-9aab-c59de09af8c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EU Wave 2 Recommending Bodies (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "f7d74bad-a886-4fb7-9f94-a9f26005d3f2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EU Wave 3 Recommending Bodies"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body meeting<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "e5aab9e2-6b39-4870-8782-89b4008ca5bf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "EU Wave 3 Recommending Bodies (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body meeting<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "red2.png",
            "id": "6b669457-fd28-4a90-8662-7b662f1f00f4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EU Wave 3 Recommending Bodies (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "red2.png",
            "id": "7b75184f-85cd-48bb-8c1b-80339a024ab5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "EU Wavw 2 Recommending Bodies"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Bernd  Salzberger,Torsten  Bauer,Johannes  Liese,Andreas  Sauerbrei,Walter  Haas,Wolfgang  Jilg,Peter  Wutzler,François  Bricaire,Michael  Pfleiderer,Christian  Rabaud,Oliver  Wichmann,Tom  Schaberg,Claude  Hannoun,Markus  Knuf,Rüdiger  Von Kries,Ulrich  Heininger,Klaus  Wahle,Catherine  Olivier-Weil,Tobias  Welte,Olivier  Patey,Bruno  Lina,Jean  Beytout,Fabrice  Carrat,Dietmar  Beier,Dominique  Peyramond,Sabine  Wicker<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/07\/2014 <br \/>until 13\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-13 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "2d25e707-8add-446f-8b9a-6c968b50fe8a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-13 12:00:00",
            "title": "Europe Regional Advisory Board (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Ulrich  Heininger,Christian  Rabaud,Fabrice  Carrat,Peter  Wutzler,Markus  Knuf,Claude  Hannoun,Catherine  Olivier-Weil,Wolfgang  Jilg,Bernd  Salzberger,Michael  Pfleiderer,Tom  Schaberg,Bruno  Lina,Rüdiger  Von Kries,Jean  Beytout,Oliver  Wichmann,Klaus  Wahle,Andreas  Sauerbrei,Johannes  Liese,Torsten  Bauer,Walter  Haas,Olivier  Patey,Dominique  Peyramond,Dietmar  Beier,Sabine  Wicker,Tobias  Welte,François  Bricaire<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/09\/2015 <br \/>until 06\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-06 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "67739743-0346-4ac7-9407-a1dfdf78dcc5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-06 12:00:00",
            "title": "Europe Regional Advisory Board (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Walter  Haas,François  Bricaire,Tobias  Welte,Bruno  Lina,Andreas  Sauerbrei,Oliver  Wichmann,Sabine  Wicker,Catherine  Olivier-Weil,Olivier  Patey,Wolfgang  Jilg,Ulrich  Heininger,Rüdiger  Von Kries,Jean  Beytout,Klaus  Wahle,Peter  Wutzler,Johannes  Liese,Torsten  Bauer,Claude  Hannoun,Fabrice  Carrat,Dominique  Peyramond,Bernd  Salzberger,Tom  Schaberg,Markus  Knuf,Michael  Pfleiderer,Dietmar  Beier<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/03\/2016 <br \/>until 13\/03\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation\/ New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-03-13 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "a827c484-6260-4482-aa05-1d857f083571",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-03-13 12:00:00",
            "title": "Europe Regional Advisory Board (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "68796f59-80ef-4126-bbbf-9b2dc214cbde",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "External Speaker's Bureau - 6 months plus indication - Q3 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  60,000 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "bba5f6cc-3e91-4914-8266-5d784bd180c7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "External speaker's bureau - Wave 2 Epi, BOD, and recommendations"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Adriana  Weinberg<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "1f5c7262-3295-4383-8ed1-f51c562a2c32",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "Face-to-face Adriana Weinberg"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Ann R  Falsey <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/02\/2014 <br \/>until 02\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-02 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "7c6c4367-6f44-4018-827d-dc1fa2f86200",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-02 12:00:00",
            "title": "Face-to-face Ann R Falsey "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Anne  Moscona<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/03\/2014 <br \/>until 02\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-02 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "3970cdf3-1c40-4e07-9a3e-426d165122dc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-02 12:00:00",
            "title": "Face-to-face Anne Moscona"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Arnold  Monto<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/04\/2014 <br \/>until 06\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-06 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "3c2d3dad-0768-4035-aa79-a7b2888a3acd",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-06 12:00:00",
            "title": "Face-to-face Arnold Monto"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Celia  Alpuche Aranda<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/05\/2014 <br \/>until 04\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-04 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "d3cb0e61-36f1-4761-a665-acbaa92de44d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-04 12:00:00",
            "title": "Face-to-face Celia Alpuche Aranda"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Douglas  Fleming<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/06\/2014 <br \/>until 08\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-08 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "3dbdc60c-1878-4b6a-99e4-0de3c448e2b5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-08 12:00:00",
            "title": "Face-to-face Douglas Fleming"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Edgar  Jimenez<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/07\/2014 <br \/>until 06\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-06 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "4ce17af8-c8e9-4e31-a2cd-fbffee6d7665",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-06 12:00:00",
            "title": "Face-to-face Edgar Jimenez"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Fabrizio  Pregliasco<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/08\/2014 <br \/>until 03\/08\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-08-03 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "6a44b339-94cb-4ec8-b3bc-aab7171446a5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-08-03 12:00:00",
            "title": "Face-to-face Fabrizio Pregliasco"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Fernando  Motta<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/09\/2014 <br \/>until 07\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-07 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "61299616-58c5-416e-9658-aba2555ab72d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-07 12:00:00",
            "title": "Face-to-face Fernando Motta "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>François  Bricaire<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/10\/2014 <br \/>until 05\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-05 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "85987662-21b1-4aa4-80dc-8bb0875db73d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-05 12:00:00",
            "title": "Face-to-face François Bricaire"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Gabriel  Leung<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/11\/2014 <br \/>until 02\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-02 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "b768f7e2-9a81-4278-8fed-fd26713c8fb7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-02 12:00:00",
            "title": "Face-to-face Gabriel Leung"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Gregory  Poland<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/12\/2014 <br \/>until 07\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-07 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "ae039011-f18e-4e60-aaf6-fac457fbb008",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-07 12:00:00",
            "title": "Face-to-face Gregory Poland "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Guillermo  Ruiz Palacios<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c8c467e4-9328-4995-afbf-439bf4850d3d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "Face-to-face Guillermo Ruiz Palacios"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Hee  Jin Cheong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 01\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c5008af8-518d-4b38-a1ce-5e0745f7f989",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "Face-to-face Hee Jin Cheong"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jenny  McKimm Breschkin<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2015 <br \/>until 01\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "06ccb7c1-318e-428d-a1a6-02f6de406543",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-01 12:00:00",
            "title": "Face-to-face Jenny McKimm Breschkin"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Joan Puig  Barbera<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/04\/2015 <br \/>until 05\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-05 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "a3ecafcc-9029-41d6-bb7c-49107ca040f9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-05 12:00:00",
            "title": "Face-to-face Joan Puig Barbera"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Joanne  Langley <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/05\/2015 <br \/>until 03\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-03 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "a9907621-6cb4-49c4-b5b8-43de37c5b210",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-03 12:00:00",
            "title": "Face-to-face Joanne Langley "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Johannes  Liese<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/06\/2015 <br \/>until 07\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-07 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "2744ceb3-8eaf-461a-92ff-284bb3940b63",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-07 12:00:00",
            "title": "Face-to-face Johannes Liese"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jonathan  Van Tam<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/07\/2015 <br \/>until 05\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-05 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "cd1d44e5-dc73-415c-84e3-eee2d2688705",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-05 12:00:00",
            "title": "Face-to-face Jonathan Van Tam "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Lance  Jennings<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/09\/2015 <br \/>until 06\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>New Zealand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-06 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "e219206d-ea93-4a5a-8cbf-f64ca9d7004a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-06 12:00:00",
            "title": "Face-to-face Lance Jennings"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Lee  Ping In<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/10\/2015 <br \/>until 04\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-04 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "2dc27c3f-8326-48ef-8790-a6136bc9f456",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-04 12:00:00",
            "title": "Face-to-face Lee Ping In"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Li Min  Huang<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Taiwan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "0c8c5e18-dea8-43b3-adc5-9f987de9e58e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "Face-to-face Li Min Huang"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Marc  Loeb<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/12\/2015 <br \/>until 06\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-06 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c765f875-2044-4c67-a1b6-5a6f4f5647fc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-06 12:00:00",
            "title": "Face-to-face Marc Loeb"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Marilda  Sequeira<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/01\/2014 <br \/>until 26\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-26 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "579d54e2-4399-4730-8f80-999a4f74d974",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-26 12:00:00",
            "title": "Face-to-face Marilda Sequeira"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Myron  Levine<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 23\/02\/2014 <br \/>until 23\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-23 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "7ffabaff-c3d4-49fa-b0ec-63e853d86fd5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-23 12:00:00",
            "title": "Face-to-face Myron Levine"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Nancy  Bellei <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 23\/03\/2014 <br \/>until 23\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-23 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "465bba6c-215c-4d97-944d-acf981e09744",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-23 12:00:00",
            "title": "Face-to-face Nancy Bellei "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Nicola  Principi<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 20\/04\/2014 <br \/>until 20\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-20 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "d39dd376-ae1b-4ca5-aceb-f737f9825b01",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-20 12:00:00",
            "title": "Face-to-face Nicola Principi"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Paul  Chan<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/05\/2014 <br \/>until 18\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-18 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "622bbe4a-7a53-4990-bb7b-403f637c9dab",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-18 12:00:00",
            "title": "Face-to-face Paul Chan"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Paul  Henri Lambert <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 15\/06\/2014 <br \/>until 15\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-15 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c988fe2d-8ec6-469c-a040-036e763df403",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-15 12:00:00",
            "title": "Face-to-face Paul Henri Lambert "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Paul  Van Buynder <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 20\/07\/2014 <br \/>until 20\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-20 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "1ff9077f-521d-415f-b686-c1065a983b6d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-20 12:00:00",
            "title": "Face-to-face Paul Van Buynder "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/09\/2014 <br \/>until 21\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-21 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "bbaea45d-8320-4bdd-b1a4-c2cb117e63d6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-21 12:00:00",
            "title": "Face-to-face Robert Belshe"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Robert  Couch <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 19\/10\/2014 <br \/>until 19\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-19 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "35c412e8-d675-402a-b648-47ec84ce559d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-19 12:00:00",
            "title": "Face-to-face Robert Couch "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Robert  Webster <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 16\/11\/2014 <br \/>until 16\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-16 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "8d1c9568-3e04-42ac-8b28-87915f0d69ea",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-16 12:00:00",
            "title": "Face-to-face Robert Webster "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Ruth  Karron<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/12\/2014 <br \/>until 21\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-21 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "f876f925-a9ef-4a87-aa43-7c8d79dda6d6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-21 12:00:00",
            "title": "Face-to-face Ruth Karron"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sanjay  K Rai<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/01\/2015 <br \/>until 18\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>India<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-18 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c8f1e567-fe17-46ca-84c1-3d49a78ec5c0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-18 12:00:00",
            "title": "Face-to-face Sanjay K Rai"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Saul  Faust<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 15\/02\/2015 <br \/>until 15\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-15 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "642548bb-d8d9-439c-9d05-59913d323868",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-15 12:00:00",
            "title": "Face-to-face Saul Faust"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sharon  Frey <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 22\/03\/2015 <br \/>until 22\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-22 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "593ce2ab-52f4-426a-a12a-1a9cf45a8f3c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-22 12:00:00",
            "title": "Face-to-face Sharon Frey "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Stanley  Plotkin<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 19\/04\/2015 <br \/>until 19\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-19 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "355704af-fbd9-4296-b37e-05b4c2757d89",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-19 12:00:00",
            "title": "Face-to-face Stanley Plotkin"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sylvie  Van Der Werf<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 17\/05\/2015 <br \/>until 17\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-17 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "21d03309-04aa-4a31-9384-df531405fb9e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-17 12:00:00",
            "title": "Face-to-face Sylvie Van Der Werf"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Timothy  Peters<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/06\/2015 <br \/>until 21\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-21 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "5aab0e6c-bda4-431d-b537-bb2db78ced3d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-21 12:00:00",
            "title": "Face-to-face Timothy Peters"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Tobias  Welte<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 19\/07\/2015 <br \/>until 19\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-19 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "fc454bd3-be3f-44c4-af58-2d27e7272e52",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-19 12:00:00",
            "title": "Face-to-face Tobias Welte"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Vladimir  Gilca <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 16\/08\/2015 <br \/>until 16\/08\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-08-16 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "c6f9fed2-5f17-4a97-9460-614905329be0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-08-16 12:00:00",
            "title": "Face-to-face Vladimir Gilca "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wolfgang  Jilg<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 20\/09\/2015 <br \/>until 20\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-20 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "a7059057-4e51-4541-9381-18b74b441ada",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-20 12:00:00",
            "title": "Face-to-face Wolfgang Jilg "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Woo-Joo  Kim<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/10\/2015 <br \/>until 18\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Continuous interaction<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-18 12:00:00",
            "high_threshold": 0,
            "icon": "dark_blue2.png",
            "id": "d7b32cf2-87b8-4b31-a559-1a49a9b9a3ff",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-18 12:00:00",
            "title": "Face-to-face Woo Joo Kim "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €50,000<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "c18eaec1-896b-4233-b12e-0941388c3ee4",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "Flu B strain in BOD in Chinese population"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jiri Beran<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 29\/11\/2011 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Czech Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase I\/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of a influenza vaccine candidate (GSK 2115160A)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "d0173a5b-54e4-463e-bdbf-f5095deb2e86",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2011-11-29 12:00:00",
            "title": "FLU D-QIV-001 PRI"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Miguel A Rodriguez Weber,Carlos Aranza-Doniz<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/05\/2011 <br \/>until 01\/11\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase II, double-blind, multicenter, randomized study to evaluate the immunogenicity and safety of GSK Biologicals quadrivalent influenza candidate vaccine GSK2321138A compared with GSK Biologicals trivalent influenza vaccine, Fluarix, administered intramuscularly in children (18-47 months of age) in both unprimed subjects and in primed subjects who previously participated in the 111751 study<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "61fad343-884a-4cda-94a8-598689960c34",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2011-05-12 12:00:00",
            "title": "FLU D-QIV-002"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Dr Hoernlein,Dr Amm,Dr Kinese,Dr Ebert,Dr Maier,Dr  Behre,Dr Kindler,Dr Loch,Dr Baukhage<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/02\/2013 <br \/>until 02\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US, France, Germany, Czech Republic, Philippines<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Clarine Claeys<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase III, double blind, randomized study to evaluate the immunogenicity and safety of GSKBiologicals’ quadrivalent influenza vaccine candidate,GSK2282512A (FLU Q-QIV), compared to GSK Biologicals’ trivalent influenza vaccine Fluarix® administered intramuscularly to children 3 to17 years of age; and to describe the safety and immunogenicity of GSK2282512A in children 6-35 months of age.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-02 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "027ebc4a-15e4-4318-b673-28ab2a3df70b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-02 12:00:00",
            "title": "FLU D-QIV-003"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 31\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Primary outcome\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "69713e4c-3d64-4d92-a225-31ad1e15cd4e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "FLU D-QIV-004 PRI (115345)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Richard M Glover,Jose Luis Fernandez,Siliva Narajos,Eric Sheldon,Jerome V Mirkil,Carmen Alvarez,Donna DeSantis,Cecil Farrington,Jose Bayas,Manuel Tern,James L Borders<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 29\/03\/2013 <br \/>until 30\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany, Romania, Spain, Korea, Taiwan, US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase III randomized, partially-blind, controlled, multi-country, multi-centre study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine FLU D-QIV (GSK2321138A) and to evaluate the clinical consistency of three production lots of FLU D-QIV in terms of immunogenicity, when administered intramuscularly to adults 18 years of age and older.\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-30 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "9fb60ddc-e44a-4a64-95aa-2185a1902b7f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-29 12:00:00",
            "title": "FLU D-QIV-008"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Esse Menson,Marie Wheeler,Richard Tomlinson,Matthew Snapp,Paul Heath,Saul  Faust,Adam Finn,Bahvesh Bodalia,Jaymur Purohit,Damien MacNally,Jenny Langlands<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Czech Republic, Poland, Spain, UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Immunogenicity and safety children 17-48 months\u000d\u000a(dates to be confirmed)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "cf0fdbba-5aa5-44f8-adf8-966bd8b99109",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "FLU D-QIV-009"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 31\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Primary outcome\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "a7557ccf-5892-4a8a-90fb-cd7f8ca544b1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "FLU D-QIV-009 EXT 004 (116023)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 22\/03\/2013 <br \/>until 22\/03\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Denmark, Germany, Spain, US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase IIa, observer-blind, multi-country, multi-centre, randomised study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals' quadrivalent influenza vaccine (QIV) adjuvented with various doses of the AS03 (GSK 2584786A), administered in children aged 6 to 35 months, and compared to non-adjuvanted QIV and FluarixTM<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-03-22 12:00:00",
            "high_threshold": 0,
            "icon": "yellow2.png",
            "id": "07820c1b-93b6-417d-b367-0a9aa6a0d507",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-03-22 12:00:00",
            "title": "FLU D-QIV-AS03-005 "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "78145b7d-f853-44d6-a698-3fd0f9277705",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "'Flu Innovation' materials and activities (splash)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC\u000d\u000a\u000d\u000aMOCK DATES ONLY - ACTUAL DATES TO BE ADDED<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "bb4ae383-f220-4ebb-a76d-0d6a655485f1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "FLU QIV IBVD retrospective A vs. B circulation ISS (116793)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Ginette Girard<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 14\/12\/2012 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A Phase IIIA, open-label, single-dose study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ quadrivalent split virion influenza vaccine (FLU-Q-QIV) in adults aged 18 years and older.\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "beb4ae66-2fc5-4db6-b775-2a1ae341a04b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2012-12-14 12:00:00",
            "title": "Flu Q-QIV-(T+)-009"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 30\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "47ca399d-4006-4171-850e-5f77e5db7417",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "FLU Q-QIV-(T+)-009 (115418) Q-TIV-012 (110628)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jose Garcia-Sicilia,Fernando Cabanas Gonzalez,Archana Chatterjee,Ronald Fischer,Naresh Aggarwal,Tai Arakai,Alfonso Carmona Martinez<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/04\/2013 <br \/>until 16\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada, Mexico, Spain, Taiwan, US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase III, double blind, randomized study to evaluate the immunogenicity and safety of GSKBiologicals’ quadrivalent influenza vaccine candidate,GSK2282512A (FLU Q-QIV), compared to GSK Biologicals’ trivalent influenza vaccine Fluarix® administered intramuscularly to children 3 to17 years of age; and to describe the safety and immunogenicity of GSK2282512A in children 6-35 months of age.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-16 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "acb90aa6-b332-4261-9e8d-7ea89a37af3a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-02 12:00:00",
            "title": "FLU -Q-QIV-003 PRI"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Kerdpanich Phirangkul,Espos Roberto,Kerdpanich Phirangkul,Dbaibo Ghassan,Chanthavanich Pornthep,Ceyhan Mehmet,Guevara Nadia,Alhan Emre,Quiambao Beatriz,Dinleyici Ener Cagn<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/01\/2013 <br \/>until 17\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Bangladesh, Dom Rep, Honduras, Lebanon, Panama, Philippines, Thailand, Turkey<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A Phase III, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion, seasonal influenza vaccine candidate, GSK2282512A (FLU Q-QIV), administered intramuscularly in healthy children 3 to 8 years of age.\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-17 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1857b75e-42bc-4659-b836-01521d96f059",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-02 12:00:00",
            "title": "FLU Q-QIV-006"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Steven Kaster,Noris Pavia-Ruz,Steven Geller,Daniel Shu,Terry Klein,Eduardo  Lazcano-Ponce,Tai Arakai,Keith Reisinger,Gerald Shockey,Jacques Hebert,Bruce Bowling<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 20\/01\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada, Mexico, US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase III, randomized, double-blind, controlled, multi-country, multi-center study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine FLU Q-QIV (GSK2282512A) when administered intramuscularly to adults 18 years of age and older\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "e748d4bb-7b11-480d-ae0b-b4d512070283",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-20 12:00:00",
            "title": "Flu Q-QIV-007 PRI (D180)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until  <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "c25b8d1a-8f34-4d84-9a51-fac681556775",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "FLU Q-QIV-013 (116926)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jenny Jiang,Mike Liu<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/06\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Phase I, adult and paediatric safety (>6 months)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "97b1c5db-2460-45c2-9d8e-cbee56931805",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "FLu S-QIV-001"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Mike Liu,Jenny Jiang<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/06\/2017 <br \/>until 01\/01\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Phase III, observer-blind, randomized controlled trial. Immunogenicity and safety of FLU S-QIV vs Fluarix®  in children 6 months to 3 years,  3–17 years of age and adults 18 years and older.\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "7b5207a2-c5ea-46b8-b5c0-30c4d1daa3d9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-06-03 12:00:00",
            "title": "FLU S-QIV-002"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Mike Liu,Jenny Jiang<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2014 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Phase I, observer-blind RCT. Reactogenicity and safety of FLU S-TIV vs Fluarix® in children 3–17 years of age and adults 18 years and older. \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "4c54d3cc-079f-4bc7-b25e-8e03a78d31c2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-04 12:00:00",
            "title": "Flu S-TIV-001"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Mike Liu,Jenny Jiang<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Phase III, observer-blind, RCT. Immunogenicity and safety of FLU S-TIV vs Fluarix®  in children 3–17 years of age  and adults 18 years and older.\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "738715de-eae0-4340-a6c7-6e77788e7af4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "Flu S-TIV-002"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "4b30967a-9866-41bb-8a20-70e014297c2b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "Flu Summit"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "0f74bebd-1f98-4c2b-b4da-bbb8d95a517c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "Flu Summit (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "363ba7f7-72ee-4df9-9dd0-c5948df814ba",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "Flu Summit (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "b27e3cac-a249-46f4-8a2d-40eb8d2103e6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "Flu Summit (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 31\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "e22d1a7d-6a53-4119-9782-59ac1915767c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Flu TIV-S-002 (116417)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 30\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "a3eddcba-b256-4761-93b8-a4772867b92b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "Flu TIV-S-002 (116418)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jiri Beran<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 29\/11\/2012 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Czech Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A phase I\/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of a influenza vaccine candidate (GSK 2115160A).<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "32dafc93-fa5f-40a2-ba39-98993e48e041",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-11-29 12:00:00",
            "title": "FLU-D-QIV-001 PRI"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "c3cade21-7f1d-4a61-9758-d84f51e8665c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "German National Influenza Meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share clinical and HE data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d53abc4b-278b-45db-9175-bda250acb4b5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "German tenders\/fixed-price Contracts (season 2014\/2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 30\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Tender dossier and meetings\u000d\u000aShare clinical and HE data\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "45fad0fa-7109-4c14-ba45-bea61c9df39b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "German tenders\/fixed-price Contracts (season 2015\/2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share clinical and HE data\u000d\u000aAs planned in the EE plan\u000d\u000a\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "f09037d0-a900-4563-b021-6822257b4e4f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "German tenders\/fixed-price Contracts (season 2016\/2017)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wolfgang  Jilg,Peter  Openshaw,François  Bricaire,Marc  Van Ranst,Marc  Loeb,Jean-Marie  Cohen,Fabrizio  Pregliasco,Jonathan  Van Tam,Ulrich  Heininger,Raul  Ortiz de Lejarazu Leonardo,Shai  Ashkenazi,Robert  Couch ,Ab Osterhaus,Markus  Knuf,Ilaria  Capua,Joanne  Langley ,Arnold  Monto,Vladimir  Gilca <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/04\/2014 <br \/>until 06\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-06 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "dc10d020-624a-426b-ae65-c783912e8582",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-06 12:00:00",
            "title": "Global Advisory Board - Adult (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Robert  Couch ,François  Bricaire,Ulrich  Heininger,Joanne  Langley ,Arnold  Monto,Marc  Van Ranst,Marc  Loeb,Ab Osterhaus,Raul  Ortiz de Lejarazu Leonardo,Fabrizio  Pregliasco,Ilaria  Capua,Jean-Marie  Cohen,Wolfgang  Jilg,Jonathan  Van Tam,Markus  Knuf,Shai  Ashkenazi,Vladimir  Gilca ,Peter  Openshaw<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 19\/04\/2015 <br \/>until 19\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-19 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "0b88f8dd-40fa-449d-b799-02bb08cd1e7a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-19 12:00:00",
            "title": "Global Advisory Board - Adult (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Vladimir  Gilca ,Jonathan  Van Tam,Joanne  Langley ,Arnold  Monto,Robert  Couch ,Raul  Ortiz de Lejarazu Leonardo,Wolfgang  Jilg,François  Bricaire,Peter  Openshaw,Marc  Loeb,Ulrich  Heininger,Ab Osterhaus,Fabrizio  Pregliasco,Shai  Ashkenazi,Ilaria  Capua,Marc  Van Ranst,Jean-Marie  Cohen,Markus  Knuf<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/07\/2016 <br \/>until 10\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-10 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "b0da4925-dc3c-4cf7-b369-1d6037e5d088",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-10 12:00:00",
            "title": "Global Advisory Board - Adult (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wolfgang  Jilg,Markus  Knuf,Joanne  Langley ,Robert  Couch ,Marc  Van Ranst,Arnold  Monto,Vladimir  Gilca ,Peter  Openshaw,Jean-Marie  Cohen,Marc  Loeb,Raul  Ortiz de Lejarazu Leonardo,François  Bricaire,Jonathan  Van Tam,Fabrizio  Pregliasco,Ulrich  Heininger,Ab Osterhaus,Shai  Ashkenazi,Ilaria  Capua<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 124,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "2eba1a17-71a6-4115-a580-db268f1467d5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "Global Advisory Board - New generation- 6 months indication - Q2 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>François  Bricaire,Vladimir  Gilca ,Raul  Ortiz de Lejarazu Leonardo,Robert  Couch ,Shai  Ashkenazi,Ab Osterhaus,Ulrich  Heininger,Fabrizio  Pregliasco,Joanne  Langley ,Marc  Loeb,Wolfgang  Jilg,Marc  Van Ranst,Peter  Openshaw,Markus  Knuf,Ilaria  Capua,Jean-Marie  Cohen,Arnold  Monto,Jonathan  Van Tam<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/07\/2014 <br \/>until 06\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-06 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "87b39620-c3bd-41a4-bb27-13c50dbbb795",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-06 12:00:00",
            "title": "Global Advisory Board - Paediatric (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Raul  Ortiz de Lejarazu Leonardo,Shai  Ashkenazi,Ulrich  Heininger,Joanne  Langley ,Robert  Couch ,Peter  Openshaw,Fabrizio  Pregliasco,Arnold  Monto,Ab Osterhaus,Markus  Knuf,Marc  Loeb,Marc  Van Ranst,Jonathan  Van Tam,Ilaria  Capua,Jean-Marie  Cohen,Wolfgang  Jilg,François  Bricaire,Vladimir  Gilca <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/07\/2015 <br \/>until 26\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-26 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "078ebd78-34a1-4e01-a60d-7a51e2ccf24b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-26 12:00:00",
            "title": "Global Advisory Board - Paediatric (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Marc  Loeb,Joanne  Langley ,Peter  Openshaw,Shai  Ashkenazi,Jean-Marie  Cohen,Wolfgang  Jilg,Fabrizio  Pregliasco,Raul  Ortiz de Lejarazu Leonardo,Marc  Van Ranst,Jonathan  Van Tam,Ilaria  Capua,Vladimir  Gilca ,Ulrich  Heininger,François  Bricaire,Markus  Knuf,Arnold  Monto,Ab Osterhaus,Robert  Couch <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 17\/07\/2016 <br \/>until 17\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-17 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "df8bd994-01a9-4009-8be6-136bcd12a2f9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-17 12:00:00",
            "title": "Global Advisory Board - Paediatric (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Ulrich  Heininger,Joanne  Langley ,François  Bricaire,Raul  Ortie Delajerazu,Peter  Openshaw,Marc  Loeb,Fabrizio  Pregliasco,Vladimir  Gilca ,Wolfgang  Jilg,Ilaria  Capua,Jean-Marie  Cohen,Robert  Couch ,Markus  Knuf,Arnold  Monto,Jonathan  Van Tam,Marc  Van Ranst,Ab Osterhaus,Shai  Ashkenazi<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>New generation: data gaps for wave 2 countries.\u000d\u000aBudget: €124000<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "dcb73a23-ecca-4593-a849-6573197c85cc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "Global Advisory Board - Uptake in Wave 2 countries"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Arnold  Monto,Raul  Ortie Delajerazu,Vladimir  Gilca ,Shai  Ashkenazi,Ab Osterhaus,Jean-Marie  Cohen,Marc  Loeb,François  Bricaire,Wolfgang  Jilg,Jonathan  Van Tam,Ulrich  Heininger,Ilaria  Capua,Peter  Openshaw,Fabrizio  Pregliasco,Markus  Knuf,Joanne  Langley ,Marc  Van Ranst,Robert  Couch <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  124,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "969204cb-6ede-4ec9-a0ad-80757598a483",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Global Advisory Board New generation: payers: Development options: game changers, cell culture, delivery methods etc."
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Seasonal influenza update\u000d\u000aBudget:  200,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "aa7bfd92-e981-45af-8a84-eb0f1bd4de4d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Global Vaccine Expert Forum"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  200,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "08c8f81d-890b-4e4a-847a-48a3bc09aaf7",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Global Vaccine Expert Forum - Seasonal influenza update - Q4 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 200,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "593524b9-fa81-424c-a33e-c54d401d2030",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Global Vaccine Expert Forum - Seasonal influenza update Q4 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Seasonal influenza update<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "873c4f13-1bfd-488c-8ed9-6b25a5c0f4eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-12 12:00:00",
            "title": "Global Vaccine Expert Forum 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 02\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Seasonal influenza update<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-02 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "f6c5b773-08ab-432c-a422-66f06c1a90d9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "Global Vaccine Expert Forum 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/11\/2016 <br \/>until 14\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Seasonal influenza update<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-14 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "d49e1c11-228e-48ae-ba61-0904d73adc54",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-11-13 12:00:00",
            "title": "Global Vaccine Expert Forum 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "93d64359-823a-4c72-8c74-0eb6af035847",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "HCSP (CTV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jean  Beytout,Jean-Louis , Bensoussan,Marianne  Fleury,Isabelle  Bonmarin,Catherine  Olivier-Weil,Jean-Claude  Manuguerra,Christian  Perronne,Sabine  Henry,Sylvie  Van Der Werf,Daniel  Lévy-Bruhl,Elisabeth  Nicand,Brigitte  Autran,Pascale  Maisonneuve,Bruno  Lina,Anne  Mosnier,Olivier  Patey,Dominique  Peyramond,Isabelle  Morer,Daniel  Floret,Fabrice  Carrat<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 09\/02\/2014 <br \/>until 09\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-02-09 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "60a875e0-6b0d-4c77-95f6-c301307f290d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-09 12:00:00",
            "title": "HCSP (CTV) 2014 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "af4d5d66-5372-4285-95d4-317c1a745493",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "HCSP (CTV) 2014 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jean-Claude  Manuguerra,Dominique  Peyramond,Anne  Mosnier,Christian  Perronne,Pierre  Veyssier,Bruno  Lina,Marianne  Fleury,Sabine  Henry,Fabrice  Carrat,Daniel  Floret,Olivier  Patey,Catherine  Olivier-Weil,Jean-Louis , Bensoussan,Pascale  Maisonneuve,Elisabeth  Nicand,Isabelle  Morer,Brigitte  Autran,Daniel  Lévy-Bruhl,Jean  Beytout,Sylvie  Van Der Werf,Isabelle  Bonmarin<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "f5fc561a-5035-4cca-92c2-a7d5d05a54a6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-12 12:00:00",
            "title": "HCSP (CTV) 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sabine  Henry,Pascale  Maisonneuve,Jean-Louis , Bensoussan,Pierre  Veyssier,Sylvie  Van Der Werf,Anne  Mosnier,Jean  Beytout,Isabelle  Morer,Dominique  Peyramond,Elisabeth  Nicand,Bruno  Lina,Catherine  Olivier-Weil,Marianne  Fleury,Brigitte  Autran,Isabelle  Bonmarin,Daniel  Floret,Jean-Claude  Manuguerra,Daniel  Lévy-Bruhl,Olivier  Patey,Christian  Perronne,Fabrice  Carrat<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/02\/2015 <br \/>until 08\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-02-08 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "69048fd3-5c90-4179-a293-564ec9d74130",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-08 12:00:00",
            "title": "HCSP (CTV) 2015 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jean  Beytout,Sylvie  Van Der Werf,Daniel  Floret,Isabelle  Bonmarin,H  Cody Meissner,Jean-Louis , Bensoussan,Olivier  Patey,Sabine  Henry,Brigitte  Autran,Isabelle  Morer,Daniel  Lévy-Bruhl,Marianne  Fleury,Dominique  Peyramond,Fabrice  Carrat,Pierre  Veyssier,Christian  Perronne,Elisabeth  Nicand,Bruno  Lina,Catherine  Olivier-Weil,Jean-Claude  Manuguerra,Anne  Mosnier<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "ddda85d8-c6cd-476e-bebe-12b01abe4407",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "HCSP (CTV) 2015 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "465add78-1252-42a4-926c-145e239d165d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "HCSP (CTV) 2015 (oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Fabrice  Carrat,Sylvie  Van Der Werf,Sabine  Henry,Marianne  Fleury,Christian  Perronne,Isabelle  Bonmarin,Daniel  Floret,Dominique  Peyramond,Daniel  Lévy-Bruhl,Brigitte  Autran,Isabelle  Morer,Elisabeth  Nicand,Jean-Louis , Bensoussan,Jean-Claude  Manuguerra,Pierre  Veyssier,Catherine  Olivier-Weil,Olivier  Patey,Bruno  Lina,Anne  Mosnier,Pascale  Maisonneuve<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/07\/2016 <br \/>until 02\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-07-02 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "676056a1-beb2-42d8-a0f2-4c63cb6e3b35",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-02 12:00:00",
            "title": "HCSP (CTV) 2016 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jean-Claude  Manuguerra,Isabelle  Morer,Fabrice  Carrat,Jean  Beytout,Sylvie  Van Der Werf,Bruno  Lina,Marianne  Fleury,Daniel  Floret,Anne  Mosnier,Elisabeth  Nicand,Olivier  Patey,Brigitte  Autran,Jean-Marie  Cohen,Sabine  Henry,Catherine  Olivier-Weil,Isabelle  Bonmarin,Pierre  Veyssier,Daniel  Lévy-Bruhl,Pascale  Maisonneuve,Christian  Perronne,Dominique  Peyramond<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/05\/2016 <br \/>until 06\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-06 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "1e5f1230-d0b7-4b40-b856-b450753b300f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-06 12:00:00",
            "title": "HCSP (CTV) 2016 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Fabrice  Carrat,Dominique  Peyramond,Jean-Marie  Cohen,Olivier  Patey,Catherine  Olivier-Weil,Anne  Mosnier,Isabelle  Morer,Daniel  Floret,Jean  Beytout,Jean-Claude  Manuguerra,Elisabeth  Nicand,Brigitte  Autran,Bruno  Lina,Sylvie  Van Der Werf,Isabelle  Bonmarin,Marianne  Fleury,Christian  Perronne,Pierre  Veyssier,Pascale  Maisonneuve,Daniel  Lévy-Bruhl<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/09\/2016 <br \/>until 10\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-10 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "f647d68a-e9a9-4ab5-a2d7-026db052f376",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-10 12:00:00",
            "title": "HCSP (CTV) 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 28\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-28 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "4c12f3e6-cfb1-42b2-bec4-6ae7946c4b59",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "HCSP (CTV) meeting "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "56fca0a1-42bf-4d32-af17-96d02baef014",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "HCSP (CTV) meeting - Recommendations Feb 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "turquoise2.png",
            "id": "75166302-fa18-4a39-ac48-b67ffbe811e7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "HE Study  (Brazil)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/01\/2014 <br \/>until 31\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Cost of illness study - Impact of mismatch influenza B in healthcare resource UK. Authors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "65963104-f466-426d-aa03-c7a0da3e840c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-31 12:00:00",
            "title": "HE-FLU-001 COI DB (116313)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/01\/2014 <br \/>until 31\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Cost of illness study - Impact of mismatch influenza B in healthcare resource UK. Authors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "11ba6899-575f-4e66-b9ef-14768e0c2743",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-31 12:00:00",
            "title": "HE-FLU-001 COI DB (116313) (Impact of mismatch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/03\/2014 <br \/>until 31\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Cost of illness study - Impact of mismatch influenza B in healthcare resource UK. Authors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "37306428-25cb-426f-adbc-74f4aa1eef98",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-31 12:00:00",
            "title": "HE-FLU-001 COI DB (116313) (Impact of strain)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 30\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Cost of illness study - Impact of mismatch influenza B in healthcare resource UK<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "64cee919-f1f3-419c-83b1-14090c070c9e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-30 12:00:00",
            "title": "HE-FLU-001 COI DB (116313) (Impact of vaccination versus no vaccination)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To evaluate the costs and outcomes of QIV versus TIV and the incremental cost-effectiveness ratio\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "7eefd80b-febb-4eca-a932-18e52b31e77a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "HO-11-755 Cost-effectiveness of QIV in the US QIV CEA - Dynamic"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Vaccination behavior in the province of Manitoba: Study will yield information on how vaccination behavior varies with factors such as geographic region, socioeconomics, physician, and previous vaccination  behavior.\u000d\u000a\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "0b11a9e2-febb-4204-a2a8-c791a7b1d0b1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "HO-12-12577 (816750)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Examining Ontario’s universal influenza immunization program with a new dynamic influenza model” (methods paper) - Disease focus.\u000d\u000aProposed authors: E. Thommes, C. Bauch, G. Meier,  (TBD) A. Chit\u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "3955529a-2aa3-4312-82d2-be2682f9cf04",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "HO-12-12617 Model 2: dynamic cost-effectiveness model Canada (353531) "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>A health economic analysis of switching from TIV to QIV in Ontario\u000d\u000aProposed authors: E. Thommes, G. Meier,  C. Bauch, (TBD)A. Chit, others…?\u000d\u000aTarget Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "183db97e-10b9-48a1-95f0-1df6174c2f54",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "HO-12-12617 Model 2: dynamic cost-effectiveness model Canada (353531) #2"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 30\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "304e658c-4ed2-493d-b34d-620c365a783a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "HSCP (CTV) meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 31\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>France<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs in EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-31 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "2fc9e92a-b157-4383-9f55-8ad0fcfc22f5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "HSCP meeting "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 31\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Further details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "600aa48d-b2c8-4dbe-a259-311c227f0fad",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "IBCAN Hospitalization and mortality in Canada"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/12\/2015 <br \/>until 06\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available. Influenza A & B Hosp and mortality<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-06 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "9b93c2f6-d263-4078-8bff-cd8e6c199dab",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-06 12:00:00",
            "title": "IBCAN Hospitalization and mortality in Canada (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit. Influenza A & B Hosp and mortality<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "624472b8-3746-485a-bee7-b2e7797f3c05",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-12 12:00:00",
            "title": "IBCAN Hospitalization and mortality in Canada (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q1 2014. Influenza A & B Hosp and mortality<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "bd051852-50dd-4c39-b548-53eb85f7f6e0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "IBCAN Hospitalization and mortality in Canada (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC\u000d\u000a\u000d\u000aMOCK DATES ONLY - ACTUAL DATES TO BE ADDED<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "af8a103c-4694-462a-818e-57ec11c2764f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "IB-FR ISS [burden hosp \/mortality] (etrack 116899)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Dates, Authors and Target Journal TBC. <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "435d7850-0fdc-4107-a6f6-c73340f5feea",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "IBGP2 (Influenza B in general practice) EPI-FLU-014 BOD EUR CRT ISS (115173)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/09\/2014 <br \/>until 09\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Washington<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-09 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "1c2ae76c-b15c-4b43-aaf9-242979e5f9d9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-06 12:00:00",
            "title": "ICAAC 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "37cecf1a-58b1-4232-a772-1a20db756c0e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "ICAAC 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5aa2289d-e0ca-4e01-b3d8-53047b108ccd",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "ICAAC 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/09\/2014 <br \/>until 09\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-09 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5b820bed-9a3d-4d3e-93ac-7a5caca41a6d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-06 12:00:00",
            "title": "ICAAC Congress"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "4bcef973-2b63-4f19-963d-a043d61516e0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "ICAAC Congress (USA)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/04\/2014 <br \/>until 04\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Cape Town<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-04-04 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "21434451-4192-4cd9-a34b-315ee0bf4abd",
            "image": "http:\/\/www.isid.org\/icid\/images\/ICID_logo.gif",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-02 12:00:00",
            "title": "ICID 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "c0fbf2bd-cc7e-4541-a13a-0e350547fe75",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "ICID 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 02\/04\/2014 <br \/>until 04\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-04 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "fd7e6b66-2353-499e-b60f-c7ffbde50113",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-02 12:00:00",
            "title": "ICID Congress (South Africa)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "Dark_blue2.png",
            "id": "c60f376f-8244-4571-9e1b-fce9945bf56b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "IDSA (IDWEEK)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "dd6191f2-4263-4be6-82b4-e23294f90b58",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-08 12:00:00",
            "title": "IDSA (IDWEEK) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "6b744072-df83-4ec5-beb3-3be4ab25b348",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "IDSA (IDWEEK) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "d003ba6b-2c2c-4201-a92c-c7540da19d1e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "IDSA (IDWEEK) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update. As planned in the EE plan. <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "98018f20-4164-4f1f-8c7f-f6d19c514864",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-08 12:00:00",
            "title": "IDSA (IDWEEK) Congress (USA TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 30\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Database analysis of incidence and cost of pediatric complications associated with influenza Retrospective analysis: 1)Demonstrate the frequency and burden associated with of clinical disease in children especially respiratory related complications some of which could have lingering effects and long-term implications.\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "408e7434-b908-4698-9e44-09382ef33d07",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "Incidence and cost of flu complications in children (HO-13-11880 )"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Johannes  Hain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €130,000\u000d\u000aCSR: Q4 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "c4c778c9-41d1-439e-b49c-4d2850742b56",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "Influenza BoD in nursing homes"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "9a04f269-e445-434a-a530-255c5e8d8eeb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "Influenza Congress (DVV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "c0ca697f-7e5d-4cf5-af47-50019a7e0642",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Influenza newsletter: pandemic and seasonal"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "839b1f24-d571-4d2e-9a5a-6d49574cfa8b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Influenza newsletter: pandemic and seasonal (quarterly)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2012 <br \/>until 01\/01\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Johannes  Hain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €100,000\u000d\u000aCSR: Q4 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "051a6654-4474-480c-8d76-1eeef211dd69",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2012-01-01 12:00:00",
            "title": "Influenza primary vs reinfection in children"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2013 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Johannes  Hain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €310,000\u000d\u000aCSR: Q4 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "9f98ca0a-0d56-487a-bae8-6ccee983383b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-10-01 12:00:00",
            "title": "Influenza-associated ICU referrals"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2012 <br \/>until 31\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Commercial activity<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "fa0b159b-0403-431d-964f-8107f638aa1c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-01 12:00:00",
            "title": "Institutional business model"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2012 <br \/>until 30\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Commercial Activity; to occur every year for 5 years<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "6960406b-44f0-4404-8b86-577c9190c691",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-01 12:00:00",
            "title": "Institutional business model (adaptations)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 30\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Congress presentations\u000d\u000aShare new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "868d7c72-3285-45af-b2d2-7c50c49ba36c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Internal Medicine"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "c09db59e-593b-4dd1-a17f-48799d14de8c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Internal Medicine 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "9c35556d-4d3f-46ea-b19d-2f575ee5fc44",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Internal Medicine 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "ba82a007-b3e4-491b-b012-24b7c4b9dc65",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "Internal Medicine 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d627b7d2-4b03-4e8d-9d7e-47623598b102",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Internal Speaker's Bureau - 6 months plus indication - Q1 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "8377f246-eaaf-443f-922b-ff100d323749",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Internal Speakers Bureau - Wave 2 Epi, BOD, and recommendations"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Beijing<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "2e930479-a0ba-4309-bebd-ca525a19d7a3",
            "image": "http:\/\/realendpoints.com\/wp-content\/uploads\/2012\/06\/ispor-logo.jpg",
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "ISPOR (APAC) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "bcd955c2-d2a5-4a06-9d6b-23c0e7441e0d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "ISPOR (APAC) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2016 <br \/>until 01\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "928ab9ae-f374-4eba-a163-5a2fc39d6365",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-01 12:00:00",
            "title": "ISPOR (APAC) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2016 <br \/>until 01\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "540cf02c-ed16-4c2c-a24a-a043503410b4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-01 12:00:00",
            "title": "ISPOR (APAC) Congress"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data. As planned in the EE plan.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "269d0ec0-3e60-4e9d-8d08-451adb4ac06b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-01 12:00:00",
            "title": "ISPOR (APAC) Congress (China)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>TBC\u000d\u000aShare new data\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "d5d813b5-22a5-4ca4-aed1-d470e3254f68",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-01 12:00:00",
            "title": "ISPOR (APAC) Congress TBC "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/11\/2015 <br \/>until 11\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-11-11 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "d9d5810c-ca47-4577-be11-e8790c78b52c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-06 12:00:00",
            "title": "ISPOR (Europe), Congress (Rome)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/11\/2014 <br \/>until 12\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Amsterdam<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-11-12 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "79df8e54-9bc7-4e53-90a4-e5413c9cff04",
            "image": "http:\/\/realendpoints.com\/wp-content\/uploads\/2012\/06\/ispor-logo.jpg",
            "importance": "40",
            "link": null,
            "startdate": "2014-11-08 12:00:00",
            "title": "ISPOR (European) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/11\/2015 <br \/>until 11\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-11-11 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "613ed842-363f-4960-8389-12a892872513",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-06 12:00:00",
            "title": "ISPOR (European) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/11\/2014 <br \/>until 12\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Congress Presentations \u000d\u000aAs planned in the EE plan\u000d\u000aShare new data<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-12 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "a38a3b7a-6d8c-48f5-a42f-d81c5b92980a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-08 12:00:00",
            "title": "ISPOR (European) Congress (Netherlands)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2016 <br \/>until 01\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "722215cd-44ba-4672-a72e-9248d40afa3e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-11-01 12:00:00",
            "title": "ISPOR (European) Congress (Poland)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2016 <br \/>until 01\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "06997844-b9ad-469b-ade5-7b911cc6638e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-11-01 12:00:00",
            "title": "ISPOR (Europre) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 04\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Montreal<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-04 12:00:00",
            "high_threshold": 0,
            "icon": "imagenta2.png",
            "id": "2c6b0202-d958-48e0-aaf5-50e3cb2c50f4",
            "image": "http:\/\/realendpoints.com\/wp-content\/uploads\/2012\/06\/ispor-logo.jpg",
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "ISPOR (International) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 16\/05\/2015 <br \/>until 20\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-05-20 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "6807e6b9-90b4-4bd1-82e4-f84f78ae5399",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-16 12:00:00",
            "title": "ISPOR (International) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "c333760e-5bc8-4bad-931a-5109f265d650",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "ISPOR (International) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/05\/2014 <br \/>until 04\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-04 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "282d3497-742b-4943-bb18-d302ca43567e",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-05-31 12:00:00",
            "title": "ISPOR (Int'l) Congress (Canada)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/05\/2016 <br \/>until 25\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-25 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "4bd131ca-0e0c-4343-85d8-d20133b45f82",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-21 12:00:00",
            "title": "ISPOR (Int'l) Congress (USA)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "b59fbac1-ee9a-4e12-bc71-a2c026cee1eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "ISPOR (LATAM) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "9c2163e7-0c0a-4c76-a72a-738b9ff1a5d2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "ISPOR (LATAM) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "6c365ba6-47c2-4975-86b6-aa28aaf2ae8a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "ISPOR (LATAM) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "b15510e8-0210-4f4c-8b87-c1f3e75a0924",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "ISPOR (LATAM) Congress"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>TBC\u000d\u000aCongress presentations\u000d\u000aShare new data\u000d\u000aAs in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "07011a31-34a4-4c40-bfdd-b410a437be7b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "ISPOR (LATAM) Congress TBC "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 16\/05\/2015 <br \/>until 20\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-20 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "42ce28cf-4aff-4ac0-a5f2-b986fddcc44c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-16 12:00:00",
            "title": "ISPOR 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "01271fe8-fb8a-4a97-92c3-1b64bb40fce7",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "ISPOR Congress (LATAM TBC) "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 03\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Date to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-03-03 12:00:00",
            "high_threshold": 0,
            "icon": "imagenta2.png",
            "id": "e5c2d289-61fd-46ea-9dca-e64748b51696",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "ISRVI 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2014 <br \/>until 01\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "5177b52b-0675-444d-bcd2-615db2d59e83",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-03-01 12:00:00",
            "title": "ISRVI Congress (South Korea) Recommendations - South Korea"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "13c92194-da41-4fca-aa03-4f2a2dc04379",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "JCVI  2014 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "36a0f07d-e1d0-46c1-a3dc-81f2c8eeea60",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "JCVI  2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "90c39e54-edcc-4fc0-a527-ff2f5e58dea5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "JCVI  2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "521704d9-b129-4492-b6b0-941357e3f22a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "JCVI 2014 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2015 <br \/>until 01\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "9930c1f1-492c-4031-96ab-dab244debecf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-01 12:00:00",
            "title": "JCVI 2015 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "d4baab3f-1996-466e-b90d-2d5fe67131e6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "JCVI 2015 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "b6bbe6b0-68ea-4b77-a6b5-5a9f5dd8e8bb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "JCVI 2016 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/06\/2016 <br \/>until 12\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-06-12 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "f00b18d8-3dd1-42fb-800c-ad3ed829c52c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-12 12:00:00",
            "title": "JCVI 2016 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "61990142-21be-4e06-b801-6bcf13d9652d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "JCVI 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "c8158bc1-6392-4bf7-8dcd-9abef17d359e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "JVCI meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>UK<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b5926821-5e2d-4caa-b868-62ef46b3f8fe",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "JVCI meeting  - Recommendations - UK"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Pablo  Bonvehi,Marilda  Sequeira,Nancy  Bellei ,Jose-Ignacio  Santos,Fernando  Motta,Celia  Alpuche Aranda,Rogelio  Perez-Padilla,Gustavo  Aristizabal,Guillermo  Ruiz Palacios,Alejando Macia,Nestor  Sosa<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/01\/2014 <br \/>until 12\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Epi and BOD 2<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-12 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "7ca0aa5d-1cb3-4e14-a068-a8061d4f19ee",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-12 12:00:00",
            "title": "LATAM Regional Advisory Board (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Nestor  Sosa,Jose-Ignacio  Santos,Celia  Alpuche Aranda,Marilda  Sequeira,Rogelio  Perez-Padilla,Fernando  Motta,Nancy  Bellei ,Alejando Macia,Gustavo  Aristizabal,Pablo  Bonvehi,Guillermo  Ruiz Palacios<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 22\/02\/2015 <br \/>until 22\/02\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-02-22 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "484b6702-c706-4b42-b274-1b11522be980",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-02-22 12:00:00",
            "title": "LATAM Regional Advisory Board (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Rogelio  Perez-Padilla,Celia  Alpuche Aranda,Jose-Ignacio  Santos,Pablo  Bonvehi,Fernando  Motta,Marilda  Sequeira,Guillermo  Ruiz Palacios,Nestor  Sosa,Gustavo  Aristizabal,Nancy  Bellei <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/02\/2016 <br \/>until 21\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-21 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "34c7cd86-eb7f-4e5d-9b69-785b3d43659e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-21 12:00:00",
            "title": "LATAM Regional Advisory Board (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Gap assessment<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "50025524-cc70-45e0-be1c-b2989c7ce88a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Literature review on burden of influenza in APAC (focus on B)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "bd40ca44-2fcd-4f72-a43a-758660c55629",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "LOC Ad Board - Epi and BOD1 Q1"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Woo-Joo  Kim,Hee  Jin Cheong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: N\/A<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "6762b865-75cf-4607-820d-aa8b26dac2f9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "LOC Ad Board - Wave 1 recommendation Q1\/2"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Woo-Joo  Kim,Hee  Jin Cheong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/03\/2014 <br \/>until 31\/03\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>South Korea<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Wave 1 recommendation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-03-31 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "85bdc496-bc8d-4255-9399-f06e2817abdb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-03-31 12:00:00",
            "title": "LOC Ad Board (Wave 1) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "d879c1af-1b87-4e7e-a940-ea6818c18d9b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Master Global Response Support"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "grey.png",
            "id": "165a154b-d9cb-44f5-8041-824d61e32804",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "Medicago QIV (approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2015 <br \/>until 01\/08\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "grey.png",
            "id": "87889287-edaa-4e43-b0e1-9d37c1ab2e79",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-08-01 12:00:00",
            "title": "Medicago QIV (filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "grey.png",
            "id": "d94cae02-88ad-43ff-b8c2-6e402e981984",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Medicago QIV (launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "b7a3c5ca-5177-4ddb-9d11-bbad0e07429e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Mexico Recommending Body"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: N\/A<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d8f59fc5-cd31-40a4-8d3b-f537b0e3f66c",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Mexico Recommending Body - Recommendations - Q4 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1012b87f-ddeb-4693-934c-27f77bc60641",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Mexico Recommending Body 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "375c407f-e049-4862-9636-34d9d2f6fb18",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Mexico Recommending Body 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommending Body<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "ab545d16-b520-48b0-aed0-2ccb3eb6c60a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Mexico Recommending Body 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 30\/06\/2014 <br \/>until 30\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To extrapolate the outcomes in peads to other populations of interest based on TIV historical evidence. Authors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "f460d33c-4a24-4b8a-82f1-763558c20eec",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-30 12:00:00",
            "title": "Model 5: Immune simulation model, using the efficacy data in Q-QIV-006 studies to assess the inferred efficacy in other populations"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "86f95788-6136-4df2-9999-70401ae48cce",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Monograph update (e.g. D-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "07235bbf-545a-40b9-96a6-a59f2e2f075e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Monograph update (e.g. Q-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Bryna  Warshawsky,Wendy  Vaudry,Shelly  McNeil,Richard  Warrington,Blair  Seifert,Bonnie  Henry,Deepali  Kumar,Nadine  Sicard,Caroline  Quach-Thanh,Marina  Salvadori,Natasha  Crowcroft<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/06\/2014 <br \/>until 08\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-08 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "4495ac4f-63ea-4584-b680-0dd63dce4946",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-08 12:00:00",
            "title": "NACI 2014 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wendy  Vaudry,Deepali  Kumar,Caroline  Quach-Thanh,Blair  Seifert,Shelly  McNeil,Bonnie  Henry,Marina  Salvadori,Nadine  Sicard,Richard  Warrington,Bryna  Warshawsky,Natasha  Crowcroft<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 12\/10\/2014 <br \/>until 12\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-12 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "978a85cb-8afa-4ff0-8e9d-35eb2d4fb6d5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-12 12:00:00",
            "title": "NACI 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Marina  Salvadori,Richard  Warrington,Wendy  Vaudry,Blair  Seifert,Natasha  Crowcroft,Bonnie  Henry,Deepali  Kumar,Shelly  McNeil,Nadine  Sicard,Caroline  Quach-Thanh,Bryna  Warshawsky<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/07\/2015 <br \/>until 06\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-07-06 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "e7a4b2e1-4a6c-4cb4-8fd0-f264b78cb865",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-06 12:00:00",
            "title": "NACI 2015 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Shelly  McNeil,Bryna  Warshawsky,Richard  Warrington,Caroline  Quach-Thanh,Natasha  Crowcroft,Wendy  Vaudry,Deepali  Kumar,Bonnie  Henry,Blair  Seifert,Marina  Salvadori,Nadine  Sicard<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/04\/2015 <br \/>until 10\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-04-10 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "f9074a97-543f-4615-9e0b-8bd22a756a80",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-10 12:00:00",
            "title": "NACI 2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Shelly  McNeil,Blair  Seifert,Caroline  Quach-Thanh,Bryna  Warshawsky,Nadine  Sicard,Wendy  Vaudry,Deepali  Kumar,Marina  Salvadori,Richard  Warrington,Natasha  Crowcroft,Bonnie  Henry<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/05\/2016 <br \/>until 06\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-06 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "366b857f-a57c-4899-8ade-d1ecc4e39116",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-06 12:00:00",
            "title": "NACI 2016 (June)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wendy  Vaudry,Nadine  Sicard,Natasha  Crowcroft,Bryna  Warshawsky,Blair  Seifert,Caroline  Quach-Thanh,Richard  Warrington,Bonnie  Henry,Shelly  McNeil,Marina  Salvadori,Deepali  Kumar<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/02\/2016 <br \/>until 10\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-02-10 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "364633af-15d2-4b2b-b3be-103bf5b00203",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-02-10 12:00:00",
            "title": "NACI 2016 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 31\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-31 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "fcc52955-2306-4937-a341-11d507139dd6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "NACI meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "6312b147-9c67-4055-84e4-aeca8783ccda",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "National Immunization Conference (NIC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2014 <br \/>until 01\/06\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "0fefb6b5-5c01-4461-9521-bfdaf2718541",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-06-01 12:00:00",
            "title": "National Immunization Conference (NIC) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2015 <br \/>until 01\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "19870841-69b0-430d-9ec4-780acaf252d1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-01 12:00:00",
            "title": "National Immunization Conference (NIC) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2016 <br \/>until 01\/06\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "d8a5027d-af56-4f9e-9a64-df5409e10bd4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-06-01 12:00:00",
            "title": "National Immunization Conference (NIC) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "0c5a0210-674c-4ee1-a988-024160c29a96",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "National Influenza Meeting in Influenza 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "c3163298-152e-4928-af0f-0d9c23a28d02",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "National Influenza Meeting in Influenza 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "57cdf04e-43fc-4bce-a46c-ad489cfc0d19",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "National Influenza Meeting in Influenza 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2015 <br \/>until 01\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Disease awareness\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "f64b3bdc-fbc1-4930-babb-0783f4f0fab9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-01 12:00:00",
            "title": "National Influenza Vaccination week"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>date to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "magenta.png",
            "id": "416cb315-331a-434c-a15b-89b6f74d5e7c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "National Influenza Vaccination week (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "5f98581e-c9d3-4ee7-ab02-e18dcdbc7be2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "National Influenza Vaccination week 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2015 <br \/>until 01\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-12-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "9f6d118b-891c-48e9-b618-b90e2be6c73b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-01 12:00:00",
            "title": "National Influenza Vaccination week 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2016 <br \/>until 01\/12\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-12-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "3489d08c-2e2d-4349-b09d-eae0b3868a98",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-12-01 12:00:00",
            "title": "National Influenza Vaccination week 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1824fc22-4356-42f3-8f81-a63202b745cf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "NFID Vaccine Research Conference"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5a5d2d09-a374-4b28-a4f8-e107e28f83c2",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "NFID Vaccine Research Conference 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "e3ec25ed-bda6-4661-9591-4644bf506d6a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "NFID Vaccine Research Conference 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Chris  Bauch,Arnold  Monto,Frederic  Hayden,Robert  Belshe,Joanne  Langley ,Gregory  Poland,Caroline  Quach-Thanh,Salah  Mahmud,Edgar  Jimenez,Fred  Henderson,Robert  Webster ,Emman  Walter,Anne  Moscona,David  Scheifele,Danuta  Skowronski,Paul  Van Buynder ,Marc  Loeb,Ruth  Karron,Blaise  Congeni,Timothy  Peters,Vladimir  Gilca ,Shelly  McNeil,Gaston  De Serres,Adriana  Weinberg<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/07\/2014 <br \/>until 13\/07\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-07-13 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "64e68b81-b62b-4841-a1fa-75bc2b314b66",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-07-13 12:00:00",
            "title": "North America Regional Advisory Board (2014)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Robert  Webster ,Fred  Henderson,Shelly  McNeil,Timothy  Peters,Paul  Van Buynder ,Blaise  Congeni,Anne  Moscona,Joanne  Langley ,Marc  Loeb,Edgar  Jimenez,Emman  Walter,Adriana  Weinberg,Frederic  Hayden,Salah  Mahmud,Caroline  Quach-Thanh,Gregory  Poland,Chris  Bauch,Arnold  Monto,Vladimir  Gilca ,Ruth  Karron,Gaston  De Serres,Danuta  Skowronski,David  Scheifele,Robert  Belshe<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 26\/07\/2015 <br \/>until 26\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-26 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "69f538f0-a0dc-4f76-97f5-f7c42d8a1b4f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-26 12:00:00",
            "title": "North America Regional Advisory Board (2015)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Frederic  Hayden,David  Scheifele,Paul  Van Buynder ,Gaston  De Serres,Salah  Mahmud,Edgar  Jimenez,Ruth  Karron,Timothy  Peters,Shelly  McNeil,Robert  Webster ,Danuta  Skowronski,Robert  Belshe,Fred  Henderson,Anne  Moscona,Arnold  Monto,Joanne  Langley ,Vladimir  Gilca ,Gregory  Poland,Adriana  Weinberg,Marc  Loeb,Caroline  Quach-Thanh,Blaise  Congeni,Emman  Walter,Chris  Bauch<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/03\/2016 <br \/>until 06\/03\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Implementation\/ New generation<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-03-06 12:00:00",
            "high_threshold": 0,
            "icon": "green.png",
            "id": "6d0cd19c-4c09-4966-8bcb-9350cd72eb94",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-03-06 12:00:00",
            "title": "North America Regional Advisory Board (2016)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "1715233c-1337-4295-8ebd-87e7decf1b6a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "Novartis Agriflu TIV (3y-18) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2012 <br \/>until 01\/02\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "af19d19a-26b8-41af-bfc9-c04193293f0e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-02-01 12:00:00",
            "title": "Novartis Agriflu TIV (3y-18) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "87c41d07-f7b8-4dc6-9439-c9b6b1069188",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Novartis Agriflu TIV (3y-18) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "85ddbf93-9211-410a-9658-bbe0fc0fa9c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "Novartis Agriflu TIV (6M-36M) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2012 <br \/>until 01\/02\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ca6acbc1-e353-4548-8aaa-8c97fc8d26da",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-02-01 12:00:00",
            "title": "Novartis Agriflu TIV (6M-36M) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "62f14b94-df83-4116-8cb1-e41602f7d695",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Novartis Agriflu TIV (6M-36M) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f0fb04a6-e410-4316-a995-2ae8533ce113",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (18+) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2012 <br \/>until 01\/02\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "af3b946a-e9e1-4d3f-a21f-c094f2bc8845",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-02-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (18+) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "809b8f17-a8c2-422b-8d00-be0c7882b286",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (18+) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2013 <br \/>until 01\/02\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "5826eece-ebd5-4e2b-ade4-86c4d36bf8da",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-02-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (3y-18y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2012 <br \/>until 01\/02\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "cb0b85b4-daa3-41fe-b4b6-ddd728ebfa07",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-02-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (3y-18y) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c55458d3-c4a0-456d-a6a7-52672fd6935c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Novartis CC Flucelvax TIV (3y-18y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "2bd620cb-259f-463e-8612-c906cec80c52",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "Novartis Fluad Ped TIV (6M-6Y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "94486861-d133-45bc-abd5-11db31e138ed",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-08-01 12:00:00",
            "title": "Novartis Fluad Ped TIV (6M-6Y) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "15ece1a2-ab14-4cea-993e-90536356b932",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Novartis Fluad Ped TIV (6M-6Y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2014 <br \/>until 01\/02\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6924aa8b-5867-412a-bbfc-b8cc088381b4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-02-01 12:00:00",
            "title": "Novartis Fluad TIV (65y+) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2013 <br \/>until 01\/08\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6d16a0ec-3fdf-4734-886a-80404cdd0f0a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-08-01 12:00:00",
            "title": "Novartis Fluad TIV (65y+) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "12be390c-9e03-483f-b2eb-dc8ee85d6dae",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Novartis Fluad TIV (65y+) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2017 <br \/>until 01\/08\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>World filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "dfa91928-6dcd-4dd2-ae86-48177173bebf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-08-01 12:00:00",
            "title": "Novartis QIV (filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2018 <br \/>until 01\/02\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>world approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "8963e0e7-da00-4b2a-962d-9486ac8f6a1e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-02-01 12:00:00",
            "title": "Novartis QIV (Global approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2018 <br \/>until 01\/09\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>world launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "9cd036c0-def8-46eb-8749-b611c768d006",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-09-01 12:00:00",
            "title": "Novartis QIV (Global launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2018 <br \/>until 01\/02\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "0aa9dfcd-d53a-4b19-aeb9-13aa31743ed9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-02-01 12:00:00",
            "title": "Novavax QIV (18-65) (approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/08\/2017 <br \/>until 01\/08\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-08-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "bd0aecf3-b849-45c3-9c3f-15100d48ae87",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-08-01 12:00:00",
            "title": "Novavax QIV (18-65) (filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2018 <br \/>until 01\/09\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "eb8c8085-853e-49a1-85bd-d99b64e6deac",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-09-01 12:00:00",
            "title": "Novavax QIV (18-65) (launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 15\/03\/2015 <br \/>until 18\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and updates\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-18 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "771c1a83-e9bf-4670-ae1c-b3138146c7be",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-15 12:00:00",
            "title": "One Health Congress (IOCH 2015) (Netherlands)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2015 <br \/>until 01\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Amsterdam<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Start: 15\/03\/2015\u000d\u000aEnd: 18\/03\/2015<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "magenta.png",
            "id": "33a00a09-c8ee-4662-9c9c-219cd4cc940e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-01 12:00:00",
            "title": "One Health Congress 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "3914aaae-f714-43c4-abb8-be8576083b3a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "OPTIONS 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Experts and update\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "728b3b11-2ff3-417e-b9ca-7355fe2bd76c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "OPTIONS Congress-Medical booth"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "dae1b741-1a30-4a9b-addf-45c49e346cf5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "OPTIONS Congress-Symposium Paediatric"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "e15d28aa-124e-401b-8f23-e15449b77672",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "PAHO  2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "023e3a8a-8d4b-4d15-8fb3-c348219e00fa",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "PAHO 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "17a87d6b-3533-4d68-9ad3-5c97590f2f31",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "PAHO meeting (LATAM TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "b8397669-cc52-4acb-8e10-b6a8b0c3f6a9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "Pediatric Academic Societies (PAS)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "2ee65f02-2a55-4ff7-8dae-cd182ab53c43",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "Pediatric Academic Societies (PAS) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "069cd0f7-28fc-452d-86b7-5254eae1977a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "Pediatric Academic Societies (PAS) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "8de97627-1d85-48f8-a6ae-c047ff595df7",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "Pediatric Academic Societies (PAS) 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 30\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Regulatory body meeting\u000d\u000aRecommendations\u000d\u000aAs in EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-30 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "55965569-35b8-4c00-bf44-43b6d729fba3",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "PEI meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b660a0db-61ef-4557-8a6c-4269a922cff8",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "PEI meeting (Germany)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "f2b569b9-73fe-46f4-b4b9-caf86f098d32",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "PEI meeting 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "bc11b4a9-ef01-4d51-b299-2c870d18a84d",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "PEI meeting 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "8c879275-0a70-4d05-b8f1-3bed75399b1c",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "PEI meeting 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2013 <br \/>until 01\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>China<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Jing Chen<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>To support recommendations and reimbursement in the designated country\u000d\u000aBudget: €50,000\u000d\u000aCSR: Q2 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "e941b977-f847-4ddf-8257-d554554944d4",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-04-01 12:00:00",
            "title": "Prospective Study B strain distribution in China"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "03481d47-b511-4efc-8a74-02620ee1e1bb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Q & A update based on new data and WISDOM "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/06\/2015 <br \/>until 30\/06\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Modify static and dynamic models to account for pediatric efficacy and complication data Cost-Effectiveness: 1)Demonstrate the cost-effectiveness of QIV given efficacy information and complication information from clinical studies and potentially support a Section 114 for QIV\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "881a8c60-1898-41a0-a167-b2c1b46d104d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-06-01 12:00:00",
            "title": "QIV model peadiatric efficacy and complications (HO-13-11882 )"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2015 <br \/>until 01\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>WHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>WHO approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "b04ba92d-305f-4d8f-a443-2e4047717582",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-01 12:00:00",
            "title": "Q-QIV 6m+ (PFS)\/MDV (WHO approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>WHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>WHO filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "766e1392-e7ad-4d5d-9687-cd44b5ec17df",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Q-QIV 6m+ (PFS)\/MDV (WHO filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c5b3c308-4249-4998-8c9f-f7290e021ebc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2015 <br \/>until 01\/05\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "39e225a9-f235-4ac6-8285-3a7573cdeb0d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-05-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI countries approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a5a8cfc5-b191-42a1-ac31-90a23af0da97",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI countries filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "95fa5548-dc04-495c-9376-f0c97e5ddb42",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI countries launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "84ff0013-dca1-4642-8300-9945714c690a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>GAVI<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>GAVI countries launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "9633ebdd-ba32-4d6e-9c64-18f8ed83139d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (GAVI launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>WHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>WHO approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "6ea109f7-b526-440f-8b04-c2b874d016c4",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (WHO approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2014 <br \/>until 01\/05\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>WHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>WHO filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-05-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "30d1ec6e-bf94-4957-9af2-e8fc1f6db4ca",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-05-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (WHO filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>WHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>WHO launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "fa89e43b-93cd-47c2-8551-59e9d4a40ae3",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV (WHO launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Dominican Republic approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "847fc5aa-c394-4756-89f5-616388b938d9",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Dominican Republic approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Dominican Republic filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "2112a606-1504-48c4-b492-e8790165c8b5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Dominican Republic filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Domincan Republic launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "94ecab26-91ac-47d1-b4ff-ce7cd3c3ee65",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Dominican Republic launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "7c4a6b33-5192-4f3d-bbc5-814097304577",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Honduras approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "06694f86-77cf-4f37-8eca-89bff9fc0d14",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Honduras filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "a379f844-1efd-4e6a-b7f0-be0dcb00d7b8",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Honduras launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "02449386-78be-4f20-a210-6bc1fcfc2a04",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (PAHO approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "bebd0a16-4c60-499d-82b4-0174d86fbce2",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (PAHO filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2018 <br \/>until 01\/01\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "c2af1b93-b413-4f34-9873-52865c49ee9a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2018-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (PAHO launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "c717ae59-4698-484d-98ca-547f0edd3892",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Panama approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "66af8e2f-6e33-40c8-97b5-154bd530b523",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Panama filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2017 <br \/>until 01\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "89277664-b2f2-4581-a7c5-cd8be79c3df4",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2017-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS (Panama launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "98b739cb-07c7-4c68-bf80-5b883bf53071",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Honduras approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "3f2697f6-0851-41c7-bd88-410d92917267",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Honduras filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Honduras<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Honduras launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "a8185414-d75b-425a-9007-bc200a7d27c2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Honduras launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "43ca55d6-1b31-4191-8731-80a2c15b688b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (PAHO countries approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "dd5fcfe0-8cc6-4235-8c4d-a1817fed09b0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (PAHO countries filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2018 <br \/>until 01\/01\/2018 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>PAHO<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>PAHO countries launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2018-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "3983b198-a5e4-4fd7-805e-0bc974f28a89",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2018-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (PAHO countries launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "5714805b-e4bd-4bc1-8393-70a32f57b885",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Panama approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "6f0c5530-0c9b-4d90-b0b8-a7b8bf2f7dac",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Panama filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Panama<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Panama launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "f99c13fc-2608-4f31-8881-f567a771253c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Panama launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Rep Domin approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "39d04ee5-78ae-4ec8-988d-c122def5db36",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Rep Domin approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Rep Domin<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "e53fff07-c2dd-4b24-baed-51ffe00bf6ef",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Rep Domin filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Dominican Republic<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Rep Domin launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "70823f4f-df93-4172-9e3a-29b2c7f4e57b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ MDV\/PFS. (Rep Domin launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia approval<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "47cba9ce-8aa9-4701-b38e-965c6328a69a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Australia approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "88551a37-80bd-435f-b7f5-3e0004f4c3cf",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Australia filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/02\/2016 <br \/>until 01\/02\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Australia launch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-02-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "7a4153c5-5106-4e6c-9579-d338d654a7db",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-02-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Australia launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Mexico approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "8634000f-8436-43d3-8801-7ca082124cd5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Mexico approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Mexico filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "bc2477e6-2056-4ae4-a643-6735a8cb6115",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Mexico filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Mexico launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue2.png",
            "id": "aaf2e7c2-dd47-4dad-8e7f-5d338e88c25d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV 6m+ PFS\/MDV (Mexico launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Brazil filing<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "8dc5939a-4df1-43ca-8fcd-d001175ed5d1",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Q-QIV SDV (Brazil filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Secondary outcome on correlate of protection\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "5f6af0f8-1d5d-4a87-8f8c-b24585a3add0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Q-QIV-006, etrack 114541"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Clinical outcomes\u000d\u000aAuthors and Target Journal TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "a84a6c2e-b1ba-40d2-8ebd-8c93bb6d8996",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Q-QIV-006, etrack 114541 #2"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/11\/2012 <br \/>until 01\/06\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><3 year indication in Canada<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1fc7f3cd-2bfa-4131-83c6-53e18512cb54",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-11-03 12:00:00",
            "title": "Q-QIV-012 (<3 year indication in Canada)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2015 <br \/>until 31\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "fe7e485d-b3ae-4da8-bb6d-d8b96898007f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-01 12:00:00",
            "title": "Q-QIV-012 (etrack TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Naresh Aggarwal,Joanne  Langley ,Luis Cousin,Paul Rheault,Allen Greenspoon,Marc Dionne,Guy Tellier,Luis Rivera<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/11\/2012 <br \/>until 01\/06\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Canada, Honduras, Dom Rep<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Varsha Jain<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><3 year indication in Canada<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-06-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "eeb5f69e-6c60-43c2-a789-548eb8800b0d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-11-03 12:00:00",
            "title": "Q-QIV-013 (<3 year indication in Canada)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  60,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "light_blue2.png",
            "id": "1cf48200-17fd-4ff7-bf26-65a600077f19",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Regional Advisory Board - Epi and BOD 1"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Jose-Ignacio  Santos,Rogelio  Perez-Padilla,Nancy  Bellei ,Marilda  De Siqueira,Nestor  Sosa,Guillermo  Ruiz Palacios,Gustavo  Aristizabal,Celia  Alpuche Aranda,Fernando  Motta,Alejando Macia,Pablo  Bonvehi<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Epi and BOD 2\u000d\u000aBudget:  60,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "4fa5f09d-0cb8-4503-a32f-f13a398771bc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Regional Advisory Board - Epi and BOD 2"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "36a16ff5-8777-44bc-b239-cb670de46d0d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Regional Advisory Board - Epi and BOD 2 - Q2 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Walter  Haas,Torsten  Bauer,Andreas  Sauerbrei,John  Edmunds,François  Bricaire,Ulrich  Heininger,Tobias  Welte,Fabrice  Carrat,Markus  Knuf,Christian  Rabaud,Wolfgang  Jilg,Michael  Pfleiderer,Klaus  Wahle,Wendy  Barclay,Claude  Hannoun,Elizabeth  Miller,John  Wood,Oliver  Wichmann,Tom  Schaberg,Dietmar  Beier,Sabine  Wicker,Johannes  Liese,Rüdiger  Von Kries,Dominique  Peyramond,Catherine  Olivier-Weil,Mark  Zuckerman,Bernd  Salzberger,Peter  Wutzler,Sylvie  Van Der Werf,Olivier  Patey,Andrew  Hayward,Jonathan  Van Tam,Bruno  Lina,Peter  White,Jean  Beytout,Pierre  Veyssier,Douglas  Fleming<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  100,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "a211b759-53b2-4a32-a0ca-d8e613914378",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation - Europe"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Edgar  Jimenez,Anne  Moscona,Gregory  Poland,Danuta  Skowronski,Shelly  McNeil,Arnold  Monto,Frederic  Hayden,Gaston  De Serres,Blaise  Congeni,Chris  Bauch,Vladimir  Gilca ,Emman  Walter,Caroline  Quach-Thanh,David  Scheifele,Fred  Henderson,Timothy  Peters,Joanne  Langley ,Marc  Loeb,Robert  Webster ,Salah  Mahmud,Adriana  Weinberg,Ruth  Karron,Robert  Belshe,Paul  Van Buynder <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 100,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "6db90217-ee03-43bc-ab0f-c3bb9f5f48b7",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation - new gen? Q3 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Pablo  Bonvehi,Marilda  De Siqueira,Nancy  Bellei ,Celia  Alpuche Aranda,Fernando  Motta,Guillermo  Ruiz Palacios,Alejando Macia,Gustavo  Aristizabal,Jose-Ignacio  Santos,Nestor  Sosa,Rogelio  Perez-Padilla<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b6d968c7-bc05-4806-adcf-5e1ed04ad983",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Regional Advisory Board - implementation - Q 1 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Wendy  Barclay,Michael  Pfleiderer,Fabrice  Carrat,Sylvie  Van Der Werf,Catherine  Olivier-Weil,Dominique  Peyramond,Peter  Wutzler,Jonathan  Van Tam,Douglas  Fleming,Oliver  Wichmann,Bernd  Salzberger,Olivier  Patey,Rüdiger  Von Kries,Pierre  Veyssier,Peter  White,Tobias  Welte,Sabine  Wicker,Christian  Rabaud,Andreas  Sauerbrei,John  Edmunds,John  Wood,Johannes  Liese,Andrew  Hayward,Walter  Haas,Bruno  Lina,Wolfgang  Jilg,Tom  Schaberg,François  Bricaire,Elizabeth  Miller,Markus  Knuf,Jean  Beytout,Ulrich  Heininger,Torsten  Bauer,Klaus  Wahle,Claude  Hannoun,Dietmar  Beier,Mark  Zuckerman<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 100,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "5f4b0c96-6674-45a1-97fd-6754361d95a4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation - Q3 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Yuen  Kwok Yung,Cissy  Kartasasmita,David  Isaacs,Li Min  Huang,Woo-Joo  Kim,Lance  Jennings,Lee  Ping In,Robert  Booy,Chow  Chun Bong,Tawee  Chotpitayasunondh,Hee  Jin Cheong,David  Smith,Shelley  De La Vega,Peter  Richmond,Lau  Yu Lung,Ian  Barr<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "7339aaab-00de-43cd-bd4f-48581bbd55eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation - Q4 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Paul  Van Buynder ,Emman  Walter,David  Scheifele,Gregory  Poland,Caroline  Quach-Thanh,Frederic  Hayden,Ruth  Karron,Robert  Webster ,Robert  Belshe,Fred  Henderson,Arnold  Monto,Gaston  De Serres,Marc  Loeb,Vladimir  Gilca ,Adriana  Weinberg,Salah  Mahmud,Anne  Moscona,Blaise  Congeni,Danuta  Skowronski,Timothy  Peters,Joanne  Langley ,Shelly  McNeil,Edgar  Jimenez,Chris  Bauch<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  100,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "31e5c816-e3b8-4b97-88c1-df4d5d7ed55e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation - US"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Edgar  Jimenez,Robert  Webster ,Fred  Henderson,David  Scheifele,Shelly  McNeil,Arnold  Monto,Ruth  Karron,Salah  Mahmud,Gregory  Poland,Paul  Van Buynder ,Emman  Walter,Frederic  Hayden,Joanne  Langley ,Adriana  Weinberg,Danuta  Skowronski,Anne  Moscona,Marc  Loeb,Chris  Bauch,Gaston  De Serres,Timothy  Peters,Robert  Belshe,Blaise  Congeni,Caroline  Quach-Thanh,Vladimir  Gilca <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 100,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "5615b8c4-3f1a-403b-9aac-4d40b32456da",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation Q3 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sylvie  Van Der Werf,Torsten  Bauer,Bernd  Salzberger,Walter  Haas,Jonathan  Van Tam,John  Wood,Claude  Hannoun,Douglas  Fleming,Markus  Knuf,Fabrice  Carrat,Sabine  Wicker,Dominique  Peyramond,Peter  White,Johannes  Liese,Mark  Zuckerman,Tom  Schaberg,Andrew  Hayward,Rüdiger  Von Kries,Elizabeth  Miller,Tobias  Welte,François  Bricaire,Catherine  Olivier-Weil,Oliver  Wichmann,Pierre  Veyssier,Wendy  Barclay,John  Edmunds,Michael  Pfleiderer,Peter  Wutzler,Andreas  Sauerbrei,Olivier  Patey,Dietmar  Beier,Ulrich  Heininger,Jean  Beytout,Klaus  Wahle,Christian  Rabaud,Bruno  Lina,Wolfgang  Jilg<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 100,000<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "8601a9aa-31c4-4c2e-9986-67db92eca953",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Regional Advisory Board - Implementation\/ New gen? Europe Q3 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Tawee  Chotpitayasunondh,Shelley  De La Vega,Lau  Yu Lung,Lee  Ping In,Peter  Richmond,Yuen  Kwok Yung,Chow  Chun Bong,Woo-Joo  Kim,Ian  Barr,Li Min  Huang,Lance  Jennings,David  Smith,Robert  Booy,Hee  Jin Cheong,Cissy  Kartasasmita,David  Isaacs<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget:  60,000.00 EUR \u000d\u000a<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "d7094e0a-5837-4a02-b7c4-d02a37795c53",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Regional Advisory Board - Recommendations"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Alejando Macia,Marilda  Sequeira,Fernando  Motta,Jose-Ignacio  Santos,Nestor  Sosa,Rogelio  Perez-Padilla,Guillermo  Ruiz Palacios,Gustavo  Aristizabal,Pablo  Bonvehi,Celia  Alpuche Aranda,Nancy  Bellei <\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>LATAM<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>udget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "24e88bc6-b2f7-49d4-b69d-ff54772ba19f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Regional Advisory Board - recommendations Q1 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "dadcadca-0b6a-4c06-92ef-f0ac8e5fa73f",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Regional Advisory Board - recommendations Q1 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Chow  Chun Bong,Li Min  Huang,Lance  Jennings,Robert  Booy,Peter  Richmond,Ian  Barr,Tawee  Chotpitayasunondh,Woo-Joo  Kim,Cissy  Kartasasmita,Yuen  Kwok Yung,David  Smith,David  Isaacs,Lau  Yu Lung,Shelley  De La Vega,Lee  Ping In,Hee  Jin Cheong<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>APAC<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 60,000 EUR<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "e0df8375-3f8a-4847-9653-1c812cbea6b0",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Regionalk Advisory Board - Implementation APAC Q4 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>David  Salisbury  ,Elizabeth  Miller,Randeep  Guleria,Art  Reingold,Joseph  Bresee,Janet  Englund,Claire-Anne  Siegrist,William  Kwabena Ampofo,Michael  Pfleiderer,Barry  Schoub,Jon  Abramson,Yu  Hongjie<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/04\/2014 <br \/>until 10\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-10 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "39a7530d-b84b-4a41-be0f-e95529484fba",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-08 12:00:00",
            "title": "SAGE 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Yu  Hongjie,Barry  Schoub,Jon  Abramson,Claire-Anne  Siegrist,David  Salisbury  ,Art  Reingold,Janet  Englund,Randeep  Guleria,Joseph  Bresee,William  Kwabena Ampofo,Elizabeth  Miller,Michael  Pfleiderer<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 31\/03\/2015 <br \/>until 02\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-02 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "5a5654fe-61ee-449f-94e0-fd13ded8d042",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-03-31 12:00:00",
            "title": "SAGE 2015 (March)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Elizabeth  Miller,Claire-Anne  Siegrist,Art  Reingold,Michael  Pfleiderer,Barry  Schoub,David  Salisbury  ,Joseph  Bresee,Yu  Hongjie,Randeep  Guleria,Jon  Abramson,Janet  Englund,William  Kwabena Ampofo<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 03\/11\/2015 <br \/>until 05\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-05 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "73f2443e-8d71-4700-b90f-45101a409dd9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-03 12:00:00",
            "title": "SAGE 2015 (Nov)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2015 <br \/>until 01\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "a1f7d525-2222-4a6a-b6d9-fe3f311e649b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-01 12:00:00",
            "title": "Sanofi Fluzone HD QIV (65y+) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "f57cf954-1f6d-4db6-b712-eeb55cba2fb9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Sanofi Fluzone HD QIV (65y+) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c1a9b4d7-9f18-41ae-8999-29c98eda0f34",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Sanofi Fluzone HD QIV (65y+) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "d30ed778-d44b-41c0-9cfe-a538ec11e7e8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "Sanofi Fluzone ID QIV (18y-60y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US Filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6939c25b-aecf-4465-b0bb-b8e49b91a436",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Sanofi Fluzone ID QIV (18y-60y) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "3baf7a6b-ce99-4ce8-8f08-29da82978ca7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Sanofi Fluzone ID QIV (18y-60y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/10\/2012 <br \/>until 18\/10\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-10-18 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "923a965d-ba35-40e7-a368-0dc2bc116d88",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-18 12:00:00",
            "title": "Sanofi Fluzone QIV  (18y-60y) (filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "42d255a6-744e-4bb0-959a-03239c43fba3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (18y-60y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "6354b68c-7c42-49d8-a827-14f3bcfdbe9d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (18y-60y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ba5a5f96-163c-4999-8193-3f8808b0b8ca",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (60y+) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/10\/2012 <br \/>until 18\/10\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-10-18 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "09c79657-9bbf-49b7-b6bf-25dafdae061a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-18 12:00:00",
            "title": "Sanofi Fluzone QIV  (60y+) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "00970f21-17a8-4793-9083-ab05d89ebac7",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (60y+) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "e480c5df-9ef8-4a0c-838f-156ae8ef0ba0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (6m-8y) (US approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/10\/2012 <br \/>until 18\/10\/2012 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2012-10-18 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "c817e2bb-da2c-4c19-8100-a76869485357",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2012-10-18 12:00:00",
            "title": "Sanofi Fluzone QIV  (6m-8y) (US filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2013 <br \/>until 01\/09\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>US launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "ba9ec9d6-f302-4e6d-9c6d-5710570f6a50",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-09-01 12:00:00",
            "title": "Sanofi Fluzone QIV  (6m-8y) (US launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/12\/2014 <br \/>until 01\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU approval date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "8a9fdedc-1400-4ef0-b3d2-47c41f3815c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-12-01 12:00:00",
            "title": "Sanofi Vaxigrip QIV (9y+) (EU approval)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU filing date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "802e4052-7906-40cb-8b19-c278eb55e202",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Sanofi Vaxigrip QIV (9y+) (EU filing)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>EU launch date<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "pink2.png",
            "id": "bb17da14-40dd-4740-a46e-21b695a12f3d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Sanofi Vaxigrip QIV (9y+) (EU launch)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "71265eb0-4218-46f3-be83-acd8b0a3437e",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "SMDM (Decision making) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Decision making\u000d\u000adate to be confirmed<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "imagenta2.png",
            "id": "f86e570f-e3fe-43ab-b91a-0b8f524bb043",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "SMDM 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Share new data\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "19dd374d-1014-4d6f-9de2-e1eb2e3e3ae1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "SMDM Congress"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Fred  Zepp,Thomas  Mertens,Hilke  Bertelsmann,Frank  Falkner Von Sonnenburg,Jan  Leidel,Hartmut  Hengel,Edeltraut  Garbe,Rüdiger  Von Kries,Ulrich  Heininger,Eva  Hummers-Pradier,Hanna  Oppermann,Stefanie  Klug,Martin  Terhardt,Sabine  Wicker,Christian  Bogdan,Marianne Van Der Sande<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/04\/2013 <br \/>until 07\/04\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-04-07 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "e6945362-9106-49c3-bac0-89f9b802e19b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-04-07 12:00:00",
            "title": "STIKO 2013 (Feb)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "25644802-1206-4f59-8405-007664bfee61",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "Stiko 2014 (Apr)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Hanna  Oppermann,Jan  Leidel,Stefanie  Klug,Sabine  Wicker,Eva  Hummers-Pradier,Thomas  Mertens,Edeltraut  Garbe,Marianne Van Der Sande,Christian  Bogdan,Rüdiger  Von Kries,Martin  Terhardt,Hartmut  Hengel,Frank  Falkner Von Sonnenburg,Hilke  Bertelsmann,Ulrich  Heininger,Fred  Zepp<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "fc2f1df3-6547-41b0-8a72-10318c504239",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "STIKO 2014 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Martin  Terhardt,Rüdiger  Von Kries,Fred  Zepp,Frank  Falkner Von Sonnenburg,Marianne Van Der Sande,Hilke  Bertelsmann,Hanna  Oppermann,Sabine  Wicker,Eva  Hummers-Pradier,Edeltraut  Garbe,Christian  Bogdan,Thomas  Mertens,Ulrich  Heininger,Jan  Leidel,Stefanie  Klug,Hartmut  Hengel<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/04\/2015 <br \/>until 05\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-04-05 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "b832f9a4-061f-485d-b645-370d90e90bfc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-05 12:00:00",
            "title": "STIKO 2015 (April)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Sabine  Wicker,Edeltraut  Garbe,Martin  Terhardt,Christian  Bogdan,Hartmut  Hengel,Thomas  Mertens,Hilke  Bertelsmann,Hanna  Oppermann,Marianne Van Der Sande,Ulrich  Heininger,Eva  Hummers-Pradier,Frank  Falkner Von Sonnenburg,Rüdiger  Von Kries,Jan  Leidel,Stefanie  Klug,Fred  Zepp<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/10\/2015 <br \/>until 08\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-10-08 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "5b906c4a-9463-49f9-8b3c-337ce549104b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-08 12:00:00",
            "title": "STIKO 2015 (Oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Hilke  Bertelsmann,Martin  Terhardt,Stefanie  Klug,Thomas  Mertens,Jan  Leidel,Hartmut  Hengel,Ulrich  Heininger,Hanna  Oppermann,Christian  Bogdan,Edeltraut  Garbe,Fred  Zepp,Sabine  Wicker,Frank  Falkner Von Sonnenburg,Marianne Van Der Sande,Rüdiger  Von Kries,Eva  Hummers-Pradier<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 10\/04\/2016 <br \/>until 10\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-04-10 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "0bb85415-035f-48ad-853c-86f1a86d66ef",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-10 12:00:00",
            "title": "STIKO 2016 (April)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em>Frank  Falkner Von Sonnenburg,Sabine  Wicker,Fred  Zepp,Marianne Van Der Sande,Edeltraut  Garbe,Martin  Terhardt,Eva  Hummers-Pradier,Rüdiger  Von Kries,Thomas  Mertens,Jan  Leidel,Hanna  Oppermann,Stefanie  Klug,Ulrich  Heininger,Hartmut  Hengel,Christian  Bogdan<\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/10\/2016 <br \/>until 06\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2016-10-06 12:00:00",
            "high_threshold": 0,
            "icon": "blue.png",
            "id": "ea64c299-92de-4377-8d12-1219c2fea105",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-06 12:00:00",
            "title": "STIKO 2016 (oct)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "771fc6d7-e876-499b-bc87-8312ed7368a3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "STIKO meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "7f26bd99-caf4-4991-8654-0f1b0a80c1db",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "STIKO\/RKI meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "426ea08b-1e5e-4c84-87bc-276319ab38f2",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "STIKO\/RKI meeting - Recommendations Germany"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "743a4f68-892c-4411-a133-e0ff32027662",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "Tender \/ Fix Price Contracts 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2015 <br \/>until 01\/09\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "ad9fccc2-b4b0-4142-bfcd-0e31c41b3a4d",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-09-01 12:00:00",
            "title": "Tender \/ Fix Price Contracts 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2016 <br \/>until 01\/09\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Germany<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "d3f8c988-97c2-48f5-8dc8-90733982f587",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-09-01 12:00:00",
            "title": "Tender \/ Fix Price Contracts 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 30\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations. As planned in the EE plan.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2014-11-30 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "3ee67e8b-3202-456f-b2d2-4b488f93ace5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "The Gerontological Society of America"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "9f4e308b-066a-49b9-bdc1-553e56fb9b85",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "The Gerontological Society of America 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "4174ed29-6a34-4c71-a6db-1f63c1875f75",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "The Gerontological Society of America 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2016 <br \/>until 01\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "0a144a68-7023-434e-b822-df9b6927ddca",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-11-01 12:00:00",
            "title": "The Gerontological Society of America 2016"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2019 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2019-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "25b3dfa3-a35d-49ba-9f06-3aad87bfdfea",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Training materials update (every 2 years)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "629f83c2-4abd-4cf4-a40a-9dbb0147c76a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Update clinical data slide kits (e.g. D-QIV in >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "79f096ac-62e4-428e-91df-9838dd7ee784",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Update clinical data slide kits (e.g. S-TIV results)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "914854c6-f269-48ac-8f9c-757bc7e0231b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Update Clinical Data Slidekits (e.g. Q-QIV data in >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "1db9c701-01ce-4889-a344-0d39774cf61f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Update core scientific slide kit  (e.g. Q-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2016 <br \/>until 01\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "ef8ef8af-5c16-4726-911b-2918ad9f3c5b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-01 12:00:00",
            "title": "Update epidemiology slide kits (e.g. mismatch South Korea in children)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>(e.g. BOD for Japan, Australia, Thailand, mismatch South Korea)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "50edf064-3a2f-4c13-85fe-3195c92d4ed6",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Update epidemiology slide kits data"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2013 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "73836814-9887-427a-8880-51bce03609ce",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2013-03-01 12:00:00",
            "title": "Update Epidemiology Slidekits (Lit review Asia Pacific)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>(e.g. models for Spain, Israel, Turkey, Thailand)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "426b409d-1c57-431d-909f-b35bfbfd3a81",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Update health outcomes slide kits"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2016 <br \/>until 01\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "6431e283-ee4e-47b7-ab0e-407d5d53d5ef",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-07-01 12:00:00",
            "title": "Update health outcomes slide kits  (e.g. adaptations)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2014 <br \/>until 01\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>(e.g. Budget optimisation model, FLO and FLORENCE models for China, HE models for Belgium, Italy, Switzerland, South Korea, Mexico, Taiwan, Hong Kong)<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "9d3a09e5-2f72-4f75-9bfe-b46eab375be8",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-01-01 12:00:00",
            "title": "Update Health outcomes Slidekits"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "e5d9cf5e-05de-45a2-b215-1c4c42ff872c",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "Update tender dossiers S-D-Q (e.g. Q-QIV >6 months, S-TIV data)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2016 <br \/>until 01\/01\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Tara Satyanand<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-01-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "71f693f7-4ed7-4ad7-ad18-2fcdca53a891",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-01-01 12:00:00",
            "title": "Update tender dossiers S-D-Q-(e.g. D-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2015 <br \/>until 01\/07\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-07-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "14f2857f-47ad-459d-8159-f91af67fcdb3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-07-01 12:00:00",
            "title": "Update value repository interactive material (e.g. Q-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "b97cd8d4-b79b-4be2-82b1-a62b971bced5",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "Update value repository material  (e.g. D-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "8d6868d9-c6a7-4e77-ae4d-7d972fb85844",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Update Value Repository Material (e.g. new epi and HE)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "5adf27fb-6c5b-4305-b4c1-61731c786a92",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "Update value repository material (e.g. Q-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2013 <br \/>until 31\/12\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>All who submit HE model and references<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Scientific Engagement Activity - annual<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "orange2.png",
            "id": "338ccd8b-cd0b-40ae-be63-c846d2c28136",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-01-01 12:00:00",
            "title": "Updates to AR and IVD as new evidence arises and country adaptations are completed"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2016 <br \/>until 01\/07\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "f608ca95-aab6-4574-8282-f221b249874b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-07-01 12:00:00",
            "title": "Value repository interactive material  (e.g. D-QIV >6 months)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Meghann Gregg<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "50de637c-1864-4725-8731-f8d8792c28c4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Wave 1 CE model (Germany + others)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 31\/12\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "221825ce-2e0e-4123-b9aa-5ecb6843f484",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "Wave 2 CE models"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 31\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>To be determined<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>All details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-31 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "2c52faa7-bd1d-481e-8e31-e252b1505c7d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "Wave 3 CE models"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "178eea30-1a77-47c7-975e-27f42c502dc0",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "WHO SAGE (Geneva) 2014"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/03\/2015 <br \/>until 01\/03\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-03-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "14a92493-b355-416c-98ef-02f8e3fba975",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-03-01 12:00:00",
            "title": "WHO SAGE (Geneva) 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Warsaw<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "96714539-62a2-421e-8e25-57ab3a768bc4",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "WHO SAGE (Geneva) 2015 (Nov)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/>All opportunities<br \/><br \/><span class='yellow'>Strategy:<\/span><br \/>Strategy 2.1 – Raise global awareness on Influenza and Influenza related burden of disease,Strategy 3.1 - Obtain universal reimbursement based on high impact value proposition,Strategy 1.2 – Raise global awareness on Influenza B burden of disease differentiating Innovative GSK IIV4s versus obsolete IIV3s and other QIVs,Strategy 1.1 - Obtain preferred\/positive Recommendations for QIVs from key scientific bodies,Strategy 2.2 - Obtain approval for the 6-35 month segment<br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "00946730-932c-45c7-ae50-1dc3f2b60864",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "WHO SAGE meeting"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2014 <br \/>until 01\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "5e61a71f-9769-4dce-a8cc-a350f99cd47e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-01 12:00:00",
            "title": "WHO SAGE meeting 2014 (Apr)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2014 <br \/>until 01\/11\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "37e829c4-5e72-45bc-9b5e-7c95df4d8039",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2014-11-01 12:00:00",
            "title": "WHO SAGE meeting 2014 (Nov)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "9568819f-222b-4893-a77a-b31e57d77cf6",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-04-01 12:00:00",
            "title": "WHO SAGE meeting 2015 (Apr)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2015 <br \/>until 01\/11\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "81500357-2108-4111-b6bc-0801b8e3bb2b",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-11-01 12:00:00",
            "title": "WHO SAGE meeting 2015 (Nov)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2016 <br \/>until 01\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "1265794e-e26b-43f6-a6cc-c5c74d9dc900",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-01 12:00:00",
            "title": "WHO SAGE meeting 2016 (Apr)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/11\/2016 <br \/>until 01\/11\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/><br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-11-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "38928f77-69d4-4d3c-9a92-acc73c2c97fe",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2016-11-01 12:00:00",
            "title": "WHO SAGE meeting 2016 (Nov)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 21\/04\/2016 <br \/>until 28\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Disease awareness\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-28 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "3e40830a-c821-4b73-9ef2-82eb91f611bf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-21 12:00:00",
            "title": "WHO World immunisation week"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/05\/2016 <br \/>until 01\/05\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Recommendations\u000d\u000aAs planned in the EE plan<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-05-01 12:00:00",
            "high_threshold": 0,
            "icon": null,
            "id": "fad7cc01-4f74-4861-a19c-4c5e10d6312f",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-05-01 12:00:00",
            "title": "World Health Assembly"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>date TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-01 12:00:00",
            "high_threshold": 0,
            "icon": "green2.png",
            "id": "0fb11317-44a0-46ff-b52e-9b582e59947a",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "WSPID 2015"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/01\/2015 <br \/>until 01\/04\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>World<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>TBC\u000d\u000aExperst and updates\u000d\u000aAs planned in the EE plan <br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-04-01 12:00:00",
            "high_threshold": 0,
            "icon": "",
            "id": "76dece2d-3732-467d-967c-b5e2a11dfe47",
            "image": "",
            "importance": "40",
            "link": null,
            "startdate": "2015-01-01 12:00:00",
            "title": "WSPID Congress (TBC)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Australia \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "cfa83260-049d-4b0d-a756-f51b8e786c0b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD Australia (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First study, first visit Q1 2014.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Australia \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "101a9831-8b54-4613-82ca-9f8021d21f30",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Australia (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Australia<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Australia \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "d297c5b7-9167-4a44-acc4-fe3f8a2e85bb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "zEPI-FLU-BOD Australia (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Belgium \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "3d217c97-5e22-41cd-9f67-bef479b89ba2",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD Belgium (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Hugo da Silva<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Q1 2014.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Belgium \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "1e8cd591-66b5-400e-a004-0c5e077d4e63",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Belgium (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/07\/2013 <br \/>until 07\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Belgium<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Belgium \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-07 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "a6bc52f2-6928-4407-8df5-5193019e83a3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-07 12:00:00",
            "title": "zEPI-FLU-BOD Belgium (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>India<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in India \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "68d3c231-9808-48f7-8185-77d819f2d239",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD India (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>India<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Q1 2014. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in India \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "113e98de-4030-4eb4-90c5-3b4e18e37dfc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD India (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/07\/2013 <br \/>until 07\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>India<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in India \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-07 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "176029f0-3e1c-429a-8df7-7d00a3730666",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-07 12:00:00",
            "title": "zEPI-FLU-BOD India (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Japan \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "3d941c6b-b33b-4183-b93e-e54d3a9ec064",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD Japan (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Q1 2014. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Japan \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "b78964af-885f-4984-be47-26b54e2b9859",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Japan (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/07\/2013 <br \/>until 07\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Japan<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Japan \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-07 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "ddd1bbd9-c31d-4b4e-a186-2c0999e341a3",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-07 12:00:00",
            "title": "zEPI-FLU-BOD Japan (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 25\/01\/2015 <br \/>until 25\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-25 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "f4aad33a-fb88-4e4c-92a0-05a0bc283328",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-25 12:00:00",
            "title": "zEPI-FLU-BOD Mexico (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "809f45ae-a65c-4279-888d-832ff4645792",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Mexico (FSFV)  "
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/07\/2013 <br \/>until 01\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/> Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "6f6924fa-c657-4838-98ac-b5d1da4765f8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-01 12:00:00",
            "title": "zEPI-FLU-BOD Mexico (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Switzerland \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "9c3c98f6-e827-4a99-90d1-c40310dd23f9",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD Switzerland (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Q1 2014.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Switzerland \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "a609d79b-8ea0-4b8b-8361-d66f26479c5e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Switzerland (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/07\/2013 <br \/>until 07\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Switzerland<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Switzerland \/ mismatch.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-07 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "9a2c2d91-6509-4024-997e-e1152f1028bc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-07 12:00:00",
            "title": "zEPI-FLU-BOD Switzerland (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit Q1 2014. Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "08d922bd-6d61-4fba-bf04-ab19629157e4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-BOD Thailand (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 07\/07\/2013 <br \/>until 07\/07\/2013 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q3 2013.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2013-07-07 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "300f8670-d1e8-451d-a323-ed7c9a6728eb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2013-07-07 12:00:00",
            "title": "zEPI-FLU-BOD Thailand  (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 04\/01\/2015 <br \/>until 04\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Thailand<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Q1 2015.  Surveillance system \/ Clinical characteristics and strain circulation of influenza B in Mexico \/ mismatch.<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-04 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "dd5c9deb-8d81-4111-9761-ae8f446b1c0a",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-04 12:00:00",
            "title": "zEPI-FLU-BOD Thailand (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/04\/2016 <br \/>until 08\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-08 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "7f0bcad1-8d77-4a48-a07f-461a3a81258d",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-08 12:00:00",
            "title": "zEPI-FLU-IBBR Hospitalization and Mortality in Brazil (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 11\/01\/2015 <br \/>until 11\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-11 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "f8e07b62-48c2-4a3f-8cc2-6aa12e0de7fe",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-11 12:00:00",
            "title": "zEPI-FLU-IBBR Hospitalization and Mortality in Brazil (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/04\/2014 <br \/>until 06\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Brazil<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-06 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "6a12dacb-d33d-45b4-aa62-02a92ce5ecd4",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-06 12:00:00",
            "title": "zEPI-FLU-IBBR Hospitalization and Mortality in Brazil (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/12\/2015 <br \/>until 06\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Dec 2015\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-06 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "be550de0-6359-4411-b911-8b3ef1ac07da",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-06 12:00:00",
            "title": "zEPI-FLU-IBIT (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/10\/2014 <br \/>until 05\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Forst subject, first visit expected Q4 2014\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "272b4ca6-47a9-4a36-8ed0-37e0ede0bbd0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-05 12:00:00",
            "title": "zEPI-FLU-IBIT (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Italy<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q1 2014\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "3f2d68c9-f502-4709-8566-cf8cbcd82fb0",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-IBIT (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 17\/04\/2016 <br \/>until 17\/04\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-04-17 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "c095360e-d0d4-4f70-b2f3-aebbc5e673fe",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-04-17 12:00:00",
            "title": "zEPI-FLU-IBMEX Hospitalization and Mortality in Mexico (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 18\/01\/2015 <br \/>until 18\/01\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-01-18 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "c9ab46c1-32b2-42f9-a575-9b49367a3d66",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-01-18 12:00:00",
            "title": "zEPI-FLU-IBMEX Hospitalization and Mortality in Mexico (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 13\/04\/2014 <br \/>until 13\/04\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Mexico<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>QIV -Flu B circulation, Mismatch\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-04-13 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "ecacbe68-034c-47ec-8d5e-9e63469adadf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-04-13 12:00:00",
            "title": "zEPI-FLU-IBMEX Hospitalization and Mortality in Mexico (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 06\/12\/2015 <br \/>until 06\/12\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR available Dec 2015\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-12-06 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "d1ecaaac-8d04-4bed-a0d3-36f6d30c1bdf",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-12-06 12:00:00",
            "title": "zEPI-FLU-IBSP (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/10\/2014 <br \/>until 05\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit expected Q4 2014\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "efe64caf-f7f2-4992-ad51-912d78c338f5",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-05 12:00:00",
            "title": "zEPI-FLU-IBSP (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 05\/01\/2014 <br \/>until 05\/01\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Spain<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q1 2014\u000d\u000aBudget: 300,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-01-05 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "53f101d7-4725-4929-a3dd-3f34e0406978",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-01-05 12:00:00",
            "title": "zEPI-FLU-IBSP (start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>First subject, first visit expected Q4 2014\u000d\u000aBudget: 1,000,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "df34754b-b153-46c9-9933-5bda554eacfb",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "zEPI-FLU-VE EUR (PMS) Vaccine Effectiveness  (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2014 <br \/>until 01\/10\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Study start Q1 2014<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "1648241b-0d65-4fd8-b2d2-2f90c8afef7e",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-10-01 12:00:00",
            "title": "zEPI-FLU-VE EUR (PMS) Vaccine Effectiveness  (Start)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 08\/01\/2017 <br \/>until 08\/01\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>Europe<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>CSR expected to be available Q1 2017\u000d\u000aBudget: 1,000,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-01-08 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "bfc822f0-d1a5-48cf-93b5-d201228ac05b",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-01-08 12:00:00",
            "title": "zEPI-FLU-VE EUR (PMS) Vaccine Effectiveness (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/04\/2017 <br \/>until 30\/06\/2017 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Catia Ferreira<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Effectiveness data output study (US)\u000d\u000aFurther details TBC<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2017-06-30 12:00:00",
            "high_threshold": 0,
            "icon": "Yellow2.png",
            "id": "76ea7028-b517-4d17-ae50-2791e860afa8",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2017-04-01 12:00:00",
            "title": "zEPI-FLU-VS-VE US (PMS)  Effectiveness data output study (US)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2016 <br \/>until 01\/10\/2016 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 1,500,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2016-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "6f66d30c-1930-4073-9c67-42a8947e8326",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2016-10-01 12:00:00",
            "title": "zEPI-FLU-VS-VE US (PMS)  Effectiveness data output study (US) (CSR)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/10\/2015 <br \/>until 01\/10\/2015 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 1,500,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2015-10-01 12:00:00",
            "high_threshold": 0,
            "icon": "brown.png",
            "id": "7e7b2219-64a1-4d3d-a881-0209e8e102cc",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2015-10-01 12:00:00",
            "title": "zEPI-FLU-VS-VE US (PMS)  Effectiveness data output study (US) (FSFV)"
        }, {
            "colour": null,
            "date_display": "no",
            "description": "<p><span class='yellow'>External expert:<\/span><br \/><em><\/em><br \/><br \/><span class='yellow'>Dates:<\/span><br \/>From 01\/09\/2014 <br \/>until 01\/09\/2014 <br \/><br \/><span class='yellow'>Location:<\/span><br \/>US<br \/><br \/><span class='yellow'>Responsible GSK contact:<\/span><br \/>Gonçalo Matias<br \/><br \/><span class='yellow'>Additional information:<\/span><br \/>Budget: 1,500,000 €<br \/><br \/><span class='yellow'>Opportunities:<\/span><br \/><br \/><br \/><span class='yellow'>Strategy:<\/span><br \/><br \/><br \/>",
            "enddate": "2014-09-01 12:00:00",
            "high_threshold": 0,
            "icon": "purple2.png",
            "id": "f67c8e9c-cfd7-409c-8fb1-b001cbaff5b1",
            "image": null,
            "importance": "40",
            "link": null,
            "startdate": "2014-09-01 12:00:00",
            "title": "zEPI-FLU-VS-VE US (PMS)  Effectiveness data output study (US) (start)"
        }],
        "focus_date": "2013-05-05 12:00:00",
        "id": "js_history 78979",
        "image_lane_height": 0,
        "initial_zoom": "25",
        "title": "Roadmap to Access (RA)"
    }]
}